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Introduction
Cardiovascular diseases (CVD) are serious public health problems with growing
substantial concern. As the leading cause of death worldwide for both biological sexes,
The Centers for Disease Control estimate that in the United States alone, 610,000
Americans die from cardiovascular diseases each year1. Unfortunately, due to the complex
physiology of the circulatory system as well as the complicated pathogenesis involved in
diseases of the heart2, a gold standard for effective primary and secondary prevention is
uncertain. Needed are evidence-based prevention programs designed to optimize health
and vascular wellness.
Cardiovascular diseases are defined broadly as disorders pertaining to the heart
and or blood vessels3. As an umbrella term for several complications, diseases of the heart
vary in regards to symptomology and levels of potential irreversible damage3,4. Diseases
of the blood vessels supplying the heart, brain, and appendages can lead to myocardial
infarction, stroke, and oxygen deprived tissue death3,4. The complexity of the risk factors
contributes to the development and pathogenesis of CVD, making direct causes elusive.
Multiple risk factors act synergistically to cause the hallmark signs of CVD, including
chronic inflammation and abnormal lipid metabolism2-4. Atherosclerosis, a precursor to
many cardiovascular complications, is recognized as a chronic low-grade inflammatory
disease of human arteries2,5 beginning within damaged vascular endothelium. In a
systematic review published in 2016, Gimbrone et al6 referred to endothelial tissue as the
“continuous cellular lining of the cardiovascular system”6. This tissue becomes damaged
by various stressors including bacterial toxins, tobacco smoke, elevated blood glucose,
1

and poor diet. The vessel wall becomes vulnerable with increased permeability, allowing
for low density lipoprotein (LDL) molecules to become trapped within the layers of the
arterial wall6. This interaction triggers a complex pathogenic cascade into motion to signal
the accumulation of macrophages, which modify the LDL particle into a premature fatty
lesion or simply, a foam cell6-9. The endothelial cells become activated by this chemical
cascade, increasing the expression of multiple chemicals secreted from damaged vessel
cells and macrophages6-9. Continued structural maturing of fatty lesions result in the
synthesis of a fibrous outer layer that protects a lipid dense, toxic core6. Gimbrone6 notes
that within one individual, multiple atherosclerotic plaques may coexist within the circulatory
system. With that, each lesion may progress at its own stage of evolution beginning with
an initial phase of endothelial dysfunction6. Dysfunction localized within the endothelial
cells may signal various developmental changes within the lesion(s)
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. Continuing this

discussion of lesion progression, this introduction will outline the integration of inflammatory
processes and lipid metabolism in the development of an atherosclerotic lesion, paying
specific attention to various biomarkers of dysfunction.
In a scientific statement written by health professionals from the Centers for Disease
Control regarding inflammatory molecules and CVD10, authors note that all stages of
development of an atherosclerotic lesion from initial injury to complication are pieces of
inflammatory response to injury10. The established lesion signals the body’s primal
response to tissue injury and contains multiple types of inflammatory cells that contribute
to instability within the plaque6-10. An increase in instability by pro-inflammatory cells may
cause the plaque to dislodge itself from the arterial wall. A ruptured plaque may travel from
2

its location of origin and ultimately occlude arteries and block blood flow to various vital
organs or appendages2-10. As a result, vital tissues stop receiving nutrients and oxygen
thus contributing to various heart disease related events, including cerebral vascular
accidents, peripherary artery disease, and myocardial infarction. Two specific inflammatory
cell types involved in atherosclerosis, cellular adhesion molecules (CAMs) and proinflammatory cytokines, are secreted from endothelial and inflammatory cells and
contribute to lesion progression2,4-10. Due to their influence on various mechanisms of
cellular function, CAMs may serve as important diagnostic markers of early endothelial
injury7. Specific CAMs of interest include intracellular adhesion molecule (ICAM) and
vascular cellular adhesion molecule (VCAM). In addition to CAMs, cytokines contribute to
plaque instability2,4, overall inflammatory response2,4 and may serve as early biomarkers
of cardiovascular risk as well as fully developed CVD2,4. Specific CVD-related cytokines of
interest include C-reactive protein (CRP) and interleukin-6 (IL-6).
Cellular Adhesion Molecules. In 1997, Devaux, et al.11 published a tissue study that
reported significant expression of cellular adhesion molecules in tissue samples from failing
human hearts11. Furthermore, Devaux notes how cellular adhesion molecules interact with
immune cells to allow for the migration of white blood cells to the site of inflammation11.
Since 1997, several studies note the selective adhesive properties of CAMs for premacrophage cells, as they are overlying the atherosclerotic plaque causing an increase in
migration of immune cells to the site of vessel damage6-11. Components of oxidized LDL
particles may act as triggers for CAM expression inducing the atherosclerotic inflammation
process6-11 suggesting that persistent ICAM expression could be a characteristic of chronic
3

inflammatory disorders11. Soluble VCAM may be present in acute damage to the
endothelium within major vessels11,12 and has been reported to be correlated with severity
or “lesion burden” in atherosclerosis6-12.
Inflammatory Cytokines. In 2004, Kanda et al13 published a systematic review
focusing on inflammatory cytokines and their clinical significance for cardiac patient care.
Researchers noted the importance of understanding cytokines for clinicians to determine
the severity of atherosclerosis as well as the role cytokines play in viral infections of the
heart muscle and cardiac tissue rejection after grafting or transplant13. Produced by
damaged endothelial cells and the immune system13, the IL6 cytokine may be a potent
activator of immune response as well as a potential stimulator of CRP and other acute
phase proteins13. Clinicians reported elevated IL6 levels within the diseased cardiac
muscle as well as in systemic circulation in the presence of heart failure while other
inflammatory biomarkers were normal13. Increased levels of circulating IL6 have been
associated with disease severity and therefore could serve as important biomarkers of
heart disease related outcomes such as unstable angina and heart failure13. In addition,
elevated levels of IL6 associated with less ability for the heart to pump blood, lower cardiac
function, and poor prognosis13. IL6 may also be an important predictor of localized cardiac
dysfunction and endothelial deterioration as it is secreted during several developmental
events noted in the timeline of maturing plaques6,13. Due to the involvement in a localized
inflammatory response, researchers speculate that this cytokine may be a crucial marker
of multiple atherosclerotic lesions; with each lesion potentially progressing at independent
rates, IL6 may be an important determinant of biological lesion stage6,13.
4

While researchers note that IL6 may serve as a better predictor of localized early
endothelial dysfunction, inflammatory cytokine CRP may serve as a more accurate
indicator of systemic wide inflammation in patients with cardiac complications2,6-9,11.
Researchers note that these two cytokines may be connected since IL6 has been found to
act as a potent stimulus of CRP production in the liver6,11. In 2013, Stoner and colleagues
investigated inflammatory biomarkers and their contribution to cardiovascular disease2. In
a systematic review, Stoner et al2 corroborates other research studies by noting that CRP
can be viewed as a predictor for future CVD events, including myocardial infarction2,6,11.
Researchers also note that due to the complexities of CVD, certain cytokines and other
inflammatory biomarkers may offer more insight to prognostic information while others may
be more instrumental in predicting cardiovascular disease events2. It is evident that chronic
inflammatory cytokines have some influence on various cardiovascular disease
complications. A reduction in inflammatory mediated pathways may contribute to improved
arterial function thus possibly contributing to a healthier heart and therefore, a reduction in
mortality.
Serum Lipid Disruption. Similar to the primal response of the inflammatory process,
the presence of tissue injury or chronic inflammation has been reported to trigger the
disruption in serum lipid levels as well as the inherent biochemical composition of lipid
molecules14,15. In 2004, Esteve et al published an article examining the relationships with
dyslipidemia, inflammation, and atherosclerosis. With activation of the inflammatory
cascade, an increase in triglycerides14 is also noted. Inflammation may also affect enzyme
activity of lipoprotein lipase, a vital player in lipoprotein metabolism14,16. Cytokines including
5

CRP and IL6 have been noted to be elevated with serum lipid disruption and to normalize
with resolving TG levels14.

In addition, rising IL6 levels have been associated with

decreasing HDL and reverse cholesterol transport. Interleukin 6 may trigger composition
changes of lipoproteins by increasing ratios of cholesterol and TG rich substances14,15. The
inflammatory process may also result in dysregulation of the LDL receptor resulting in
accumulation of particles, which are prone to oxidation14,15. Oxidized LDL is more
pathogenic and may serve as important precursors to foam cells, a premature
atherosclerotic lesion14. Together these findings further reinforce the proposed integration
of lipid metabolism within the inflammatory cascade.
It is evident that the inflammatory response to endothelial injury acts synergistically
with molecules of lipid metabolism thus contributing to cardiovascular disease related
outcomes. Lifestyle approaches for both primary and secondary prevention of CVD as well
as chronic inflammation and dyslipidemia that highlight healthy dietary intake have become
the focus of many treatment modalities. Recently praised in the Scientific Report of 20152020 Dietary Guidelines17, the Mediterranean diet is a dietary pattern with promising health
benefits. In addition, Mediterranean areas have lower morbidity rates and increased
longevity18. The Mediterranean Diet (MD) refers to the dietary pattern of its location. First
introduced by Dr. Ancel Keys in the 1960s18, the MD combines a variety of minimally
processed food groups in moderation to provide a balanced, satiating meal pattern18. The
MD emphasizes the consumption of monounsaturated and polyunsaturated fats (primarily
in the form of olives, olive oil, and nuts) as well as the daily consumption of vegetables,
fruits, low fat dairy products, and whole grains18,19. In addition to these guidelines,
6

consumption of fish twice weekly, poultry, legumes, and tree nuts are recommended. Eggs
may be consumed 7 days a week. Individuals following the MD are encouraged to reduce
the servings of processed items and red meat to at least 1-2 times per week. Moderate
consumption of alcohol (in the form of wine at 1 drink/day for women and 2 drinks/day for
men) is allowed. Physical activity to promote health and overall well-being is encouraged.
In addition, the nutritional guidelines note that these dietary factors specific to the
Mediterranean diet are contributors to a reduction in metabolic disturbances commonly
seen in individuals that consume a poor quality diet17. The report defines a suboptimal diet
is as a dietary pattern with low fruit and vegetable intake, infrequent consumption of
seafood, nuts, and legumes with increased consumption of sodium rich and processed
foods17. These characteristics of poor diet quality are eliminated when one follows a
Mediterranean diet.
The Mediterranean diet and various health complications have been a focus of many
types of research efforts including retrospective, prospective, and clinical trials. Among
important literature, both the Lyon Heart Study (LHS)20 and the Prevención Con Dieta
Mediterránea (PREDIMED)21 have been sources of promising evidence in relation to
reducing and preventing CVD events. These studies were the first to investigate the
cardio-protective effect of the Mediterranean diet on cardiovascular disease events using
a randomized and controlled setting. The LHS compared a traditional MD to a control diet
while the PREDIMED trial investigated the effect of enhanced Mediterranean diets with
olive oil and nuts versus a low fat diet only. The PREDIMED trial extended MD investigation
by questioning key food components of the MD pyramid21. One of the first randomized
7

control trials with a longitudinal premise to investigate the cardio protective effect of the
Mediterranean diet, the PREDIMED study spanned eleven primary care facilities across
Spain and continues to deliver positive results. Cited in many research reports, these rather
historical studies have outline beneficial effects of the MD for both cardiovascular disease
and inflammation. Chiva-Branch et al5 cites PREDIMED results in a systematic review:
greater adherence to MD is associated with a reduction in CVD events and related
deaths5,21. After 5 years, a relative risk reduction of major CVD events (MI, stroke, death)
by 30%5,21. In addition, Chiva-Branch notes that two sub-studies of the PREDIMED trial
revealed that after a 3-month MD dietary intervention a reduction in serum expression of
CRP was observed5. In another sub-study of PREDIMED, researchers were able to
attribute these serum reductions to increased adherence to the MD as well as increased
consumption of extra virgin olive oil, nuts, fruits, and vegetables5.
Many research efforts in addition to the PREDIMED21 study have taken further steps
to look closer at the specific roles of olive oil and tree nuts in the beneficial responses
observed by individuals following the Mediterranean diet. As mentioned above, both olive
oil and tree nuts are priniciple sources of dietary fat within the Mediterranean diet
pattern18,19. In a report published by Rigacci et al75, the nutraceutical properties of olive oil
in particular are discussed as well as their proposed benefits noted specifically for
inflammatory atherosclerosis and CVD. Olive oil contains strong antioxidant properties that
pose as a potent combator of localized and systemic inflammatory responses seen in
atherosclerotic disease75. Specific polyphenols isolated in the olive plant have been noted
to favor longevity while reducing the inherent inflammatory response75. In regards to tree
8

nuts, Souza et al76 notes a nutrient profile containing high levels of bioactive substances
that influences a reduction in oxidative stress causing a protective effect against
cardiovascular alterations76. In addition to these findings, Souza et al76 discusses the
importance of consuming a mixture of nuts to help intensify the cardio-protective and antiinflammatory benefits attributed to nuts76. Researchers describe a “balancing effect of
nutrients” such as mono- and poly-unsaturated fats and minerals to targe specific disease
related markers involved in atherosclerotic cardiovascular disease76. Due to the growing
body of evidence pertaining to the Mediterranean diet pattern and its principal sources of
dietary lipid (olive oil and nuts specifically), it is important to consider these key components
of the MD as they do not diminish the overall dietary quality.
Taken together, these positive findings in regards to the MD dietary pattern, its key
sources of lipid, and CVD support the beneficial effect of a Mediterranean diet pattern.
However, it still remains unclear which particular characteristics of the MD interventions
influence the greatest beneficial effect on cardiovascular disease events, inflammatory
biomarkers, and serum lipid measures. It is also important to note that many of the current
reports on MD and CVD yield controversial results and make it difficult for researchers to
observe the efficacy of a dietary pattern over time and across multiple populations. These
findings suggest further investigation is warranted to understand the connection between
the Mediterranean diet patterns, cardiovascular disease events, and inflammatory
cytokines.
Purpose and Specific Aims
The purpose of this work is to study the relationship of the MD and cardiac related
9

events as well as potential diagnostic markers of disease severity by conducting a high
quality meta-analysis. Due to the nature of the extracted data, two researchers and a third
party expert (TBHM) recommended two different Meta analytic approaches a univariate
(using fixed and random-effects assumptions) and a multivariate (using random-effect
assumptions) approach; both approaches will include mixed-effects assumptions when
predictors are included in the models. In addition to CVD related events and inflammation,
the majority of studies included serum lipid measures as outcomes. Due to the apparent
integration of inflammation and lipid metabolism as well as the increasing burden of CVD
related complications, the following outcome measures were chosen for evaluation under
both random-effect assumptions: 1) total CVD related events, 2) myocardial infarction, 3)
CVD related death, 4) c-reactive protein, 5) interleukin 6, 6) intracellular adhesion
molecule, 7) vascular cellular adhesion molecule, 8) triglycerides, 9) low density
lipoprotein, and 10) high density lipoprotein. Due to the nature of included data as there
are multiple subgroups per study, researchers determined a multilevel meta-analytic model
was implemented to account for dependencies within the dietary comparisons. Therefore,
under multivariate assumptions the following outcome measures were chosen for further
investigation: CRP, IL6, ICAM, VCAM, TG, LDL, and HDL.
Several specific aims under each Meta analytic approach are outlined in detail below
with the analysis performed.
Univariate Meta-Analytic Aims.
1. to obtain overall effect sizes under fixed- and random-effects assumptions for each
outcome of interest (total CVD related events, MI, CVD death, CRP, IL6, ICAM,
10

VCAM, TG, LDL, and HDL)
2. to evaluate the variability/consistency across current available literature pertaining
to this topic
3. to explain the variability across the study population using the moderator or predictor
variable, intervention length
Multivariate Meta-analytic Aims.
1. to obtain overall random effect sizes for each outcome of interest (CRP, IL6, ICAM,
VCAM, TG, LDL, and HDL) while accounting for multiple dietary comparision groups
within each included study
2. to evaluate the variability/consistency across current available literature pertaining
to this topic by examining the differences between each dietary comparision group
3. to further explain the variability across the study population using moderator or
predictor variables coded during the data extraction process
The primary hypothesis for this paper is that both random and multilevel effects for
outcomes of interest (CVD related events, inflammatory biomarkers, and serum lipid
markers) will favor the Mediterranean diet interventions compared to baseline with a null
hypothesis that the MD will have no impact on CVD related outcomes of interest. The
second hypothesis is that the efficacy of the MD interventions with differ across studies for
each of the outcomes in question; some interventions will have significant effect while
others will not, allowing researchers to indicate benefit of the MD interventions over the
control group. Particularly under multilevel assumptions, the individual Mediterranean diet
11

comparison groups will significantly differ from one another and will allow researchers to
begin to observe dietary dominance of effect. The final hypothesis of this paper is that
moderator or predictor variables related to sample characteristics and dietary intervention
design will help explain potential sources of heterogeneity in both univariate and multilevel
models.
Methods
Literature Search. Research studies published up until July 17th, 2015 were
considered for the study sample. A comprehensive literature search was conducted with
the assistance of the University of Connecticut Health Sciences librarian (JL), using a
Boolean search approach with appropriate key words and Medical Subject Headings
(MeSH). Examples of these search terms include, “Mediterranean diet,” “Mediterranean
style diet,” “cardiovascular disease,” “heart disease,” “myocardial infarction,” “heart attack”,
“stroke,” and “atherosclerosis.” Seven databases were searched including: PubMed,
CINAHL, EMBASE (via Scopus), Academic Search Premier, PsycINFO, Agricola, and CAB
direct, suggesting a comprehensive search strategy. Language was not restricted in these
searches and translators were used when applicable. Please refer to Appendix 1 to view
the comprehensive search details for each database. In addition to computer-assisted
programs and electronic data base searches, all studies from Schwingshackl et al22 were
also screened for inclusion. Please refer to Appendix 2 to review the study screening form
used throughout the inclusion process. A list of excluded studies with corresponding
reasons for exclusion is available upon request.
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Selection Criteria. Original research articles that presented pre- and post- design
results regarding MD and CVD related events (specifically, CVD related deaths and or
myocardial infarctions) and or MD and at least one inflammatory biomarker of interest
(CRP, IL-6, ICAM, VCAM) were included for analysis. Lipid measures were not a direct
inclusion criterion rather merely a secondary analysis as the majority of reports reported
both measures of inflammation and dyslipidemia. Reports investigating the efficacy of a
balanced Mediterranean diet and or an enhanced Mediterranean diet with additional
servings of olive oil or nuts on desired outcomes of interest were included for this analysis.
Studies that did not provide baseline and post intervention data for CVD related deaths,
heart attacks, or inflammatory biomarkers of interest were excluded. In addition, studies
that focused only on specific particular components of the MD (such as just seafood, wine
only, just olive oil, or nuts only) were excluded from analysis. Reports that failed to report
necessary information to calculate effect sizes were also excluded. Relevance of included
studies was assessed based on topic, keywords, title, and abstract by two independent
researchers (JS and MC) using a hierarchical approach. Researchers consulted an
additional third party expert (TBHM) when needed to resolve disagreements regarding
inclusion and exclusion criteria. The initial search yielded a total of 1,019 abstracts with
relevant key words. After screening, hand searching, and organizing studies, 27 studies
with a total of 229 comparisons were included for meta-analytic analysis. These studies
met our inclusion criteria and focused on the efficacy of a Mediterranean diet on CVD
related deaths, myocardial infarction, and inflammatory biomarkers. Refer to Figure 1 to
view a Preferred Reporting Items for Systematic Reviews and Meta-analyses or PRISMA
13

flow diagram of inclusion and exclusion process. A list of excluded articles with reasoning
is available upon request.
Data extraction. A team of three Registered Dietitians, a physician, and a
Biostatistician developed the comprehensive data extraction form and accompanying
protocol originally in July 2014. The protocol included a manual and a data extraction form
developed to guide our specific aims and hypotheses as well as to extract or code for
information pertaining to sample characteristics including ethnicity, region and gender,
intervention characteristics including length, diet type, macronutrient distribution, caloric
intake, and participation in dietary counseling, as well as study design characteristics
including experimental settings, control group, and number of interventions. The coding
form and its manual included a total of 330 descriptive variables and other variables related
to the general purpose of evaluating MD efficacy; both documents were initially pilot tested
by two independent researchers in July 2014 (JS and MG) before a final review by
additional experts (JB, JK, AK, TBHM). The data extraction form was later edited in August
2015 for purposes of the new specific aims and hypotheses of this study and to ensure that
researchers obtain necessary information from included studies. Each study was
independently reviewed and coded by two independent researchers (JS and MC).
Discrepancies were resolved between the two investigators privately or with the help of a
third expert when necessary (TBHM). Refer to Appendix 3 to view the comprehensive
coding form and corresponding data extraction manual.
Risk of Bias. To assess risk of bias within included studies, the Cochrane
Collaboration’s risk of bias tool was utilized23. With this tool, researchers score items with
14

either a minus sign (“-“) indicating high risk of bias; a plus sign (“+”) indicating moderate
risk of bias; or a double plus sign (“++”) indicating low risk of bias for that parameter in
question. Please refer to Figure 14 to review a graphical representation of Cochrane’s risk
of bias tool. A total of 8 parameters were assessed addressing quality control issues
relating to participant randomization procedures, subject allocation methods, blinding of
subjects and personnel, attrition bias, and selective reporting. Methodological quality (MQ)
rankings have been identified as an under- analyzed element of the data reported in metaanalyses24-26. In this meta-analysis, MQ ratings calculated using a combined tool based on
both Miller27 and Jadad’s28 methodological quality rating scales. Scores were coded
individually and then totaled as separate variables for coding purposes. MQ was introduced
as a possible moderator for multilevel analysis.
Effect sizes. Individual effect sizes (ES) were calculated for each intervention with
desired outcomes of interest to assess the magnitude of change observed for the
Mediterranean dietary intervention. ES were calculated as the standardized mean
difference, d 38. The standardized mean change is the difference between the pre-test and
post-test means for the sample in question, divided by the pre-test or post-test standard
deviation40. This allows for the comparison and or combination of results from several
different study designs resulting in the elimination of the need to omit studies based on
design differences. Individual effect sizes for each outcome were determined by calculating
the standardized mean change for each study sample using data from various sources40.
The data extracted for individual effect size analysis could be presented as means±s.d., ttest, F- ANOVA, or mean±s.d. change, among other units and using the calculator the
15

different statistical information is transformed in a common metric, d, across comparison
and studies. Individual effect sizes were calculated using an Excel calculator created by
Huedo-Medina et al39. The effect size index, d+, follows a normal distribution from negative
infinity to positive infinity, containing zero as the null value31. According to Cohen’s
classification, the magnitude of the d value can be interpreted as 0.25 for small effect, 0.5
for median effect, and 0.8 for large effect of outcomes of interest31.
Statistical Analysis. All descriptive statistics about the study population were
calculated using Excel29. Inter-Rater Reliability (IRR) was conducted for all categorical and
continuous variables using IBM SPSS version 2230. Agreement of categorical variables
were represented by the Kappa (κ) coefficient31and Pearson’s correlation coefficient32 was
used to calculate continuous variable agreement. We tested for publication bias or
asymmetries using two inferential tests, Begg33 and Egger’s34 as well as two graphical
tests, the trim-and-fill method35 and funnel plots36. Remaining single level and multilevel
statistical analyses with introduction of predictor variables was conducted using R version
3.1.2 “Metafor” package37. All code for these analyses can be found in Appendices 4 and
5.
In addition to individual effect sizes, weighted fixed and random overall effect sizes
were calculated at univariate and multivariate level41. The fixed effect model assumes that
the data is coming from the same population thus only accounting for within study
variance41. The random effect model assumes the data originates from multiple study
populations thus accounting for both within and between study variance41. Mixed-effects
models were run also using different predictors in the model. In addition to a univariate
16

meta-analytic approach, random- and mixed-effect models were developed for multivariate
analysis by incorporating the inner and outer study variance covariance matrix, within the
multilevel model. To test for heterogeneity, Cochran’s Q and I2 were calculated. Cochran’s
Q tests for significance of heterogeneity42,43 while I2 represents the proportion of betweenstudy variability out of the total variablility44, presented in a numerical range from 0-100%.
Following our hypotheses, moderator analysis utilizing mixed-effect models with maximum
likelihood estimation of random-effect weights was performed using the variable length of
intervention or number of weeks. To do so, the moving the constant technique44 was
implemented to obtain estimates of the ES (d+) at various levels of the moderator variable.
Corresponding confidence intervals (Cis) were obtained at different levels of interest. This
technique was used to investigate the effect at minimum and maximum levels of the
moderator variable weeks.
A multivariate or mixed effect approach was then implemented due to the fact that
many studies included in this paper contain multiple dietary interventions as well as primary
and secondary endpoints. This type of hierarchy leads to a nested structure within the data
set that needs to be accounted for42,45,46. These four interventions were categorized into:
balanced Mediterranean diet (BMD), mixed nut enhanced Mediterranean diet (MDN), olive
oil enhanced Mediterranean diet (MDOO), and control. The dietary interventions are
clustered within reports resulting in significant dependencies related to the presence of
multiple dietary interventions, which needs to be addressed. Ignoring dependencies within
a data set can lead to bias within standard errors. This mistake would result in a Type 1
error with an inflated α level45. To account for the nested structure and dependencies one
17

can explore more potential causes of heterogeneity by introducing explanatory or predictor
variables to assess their influence on the magnitude of the effect size. In addition,
correlations and associations between comparison groups may be observed and
evaluated45. When interpreting multilevel results, the test for moderators or QM as along
with its corresponding p.value should be noted. The QM is an inference test that helps
determine model fit. A p.value of 0.05 or less indicates good model fitness.This value
assists researchers in determining if the weighted effect sizes were significant and varied
between each dietary comparison group. The individual p.values associated with each
dietary comparison should correlate with the QM p.value and represent the significance of
variability between dietary interventions within the multilevel model.

Results
Description of Included Studies. Inter-rater reliability testing resulted in a Kappa (k)
coeefcient of 0.93 representing a 93% agreement between two independent coders for
categorical variables. Pearson’s coefficient of r=1 was obtained for continuous variables.
In total, there were 229 separate dietary interventions clustered within the 27 reports
included for analysis. A description of included studies can be found in Table 1. Out of 27
reports, only 19% of studies (5) measured cardiovascular disease related deaths and or
myocardial infarction. In sum, the studies contained 20,937 participants with an average of
mean age (SD) of 54(13.10) years. Participants involved in studies that measured CVD
related events totaled 15,974 individuals and had existing CVD risk factors or cardiac
complications. Subjects on average mostly male (30.2% or n=6324 were female).
18

Individuals involved in studies that did not measure CVD events had either CVD risk
factors, dyslipidemia, metabolic syndrome, diabetes mellitus, hypertension, obesity or a
combination of these diseases. Table 1 describes disease type noted for each specific
study. Depiction of baseline health status was provided in all 27 (100%) studies but only
described the type of disease and or CVD risk factors as well as serum biomarkers at the
beginning of intervention. Medications were not a part of any intervention however, 11
(41%) studies reported continuance of drug regimens when deemed necessary on a per
subject basis. In total, 16 (59.3%) interventions allowed current smokers in the studies.
Over half of the included studies,18 reports in total (66.7%) did not specify weight loss as
a result of interest; weight loss was not reported in these studies. A total of 20 studies
(74.07%) were conducted in Europe, 3(11.11%) were conducted in the United States, 2
(7.40%) in Australia, 1 (3.7%) in Africa, and 1 (3.7%) in Asia. All reports were published in
English. The studies were published between 1994 and 2015 (mean = 2008, SD = 5.29).
The average impact factors is 10.93 (SD =14.25). Both one-on-one intervention and small
group intervention levels were measured in 19 (70.3%) of the included studies. The
minimum intervention length was 8 weeks and the maximum intervention length was 208
weeks (mean=50.31, SD=58.58). No significant asymmetries were found using either
statistical tests or the graphical techniques. A summary of the publication bias results can
be found in Table 2.
Univariate Approach
Random Effects. Please refer to Table 3 for an overall summary of univariate results
with corresponding Q and I2 values. Overall the Mediterranean diet had beneficial effects
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for 9 out of 10 outcomes of interest. Weighted effect sizes modeled under random effects
assumptions attest that the MD had a significant overall effect on total cardiovascular
related events (d+=-0.37, 95% CI -0.57 to -0.17), myocardial infarctions (d+=-0.32, 95% CI
– 0.57 to -0.08), and CVD related death (d+=-0.44, 95% CI -0.78 to -0.089). The
Mediterranean diet interventions exerted a favoring response on inflammatory biomarkers
CRP (d+=-1.02, 95%CI -1.70 to -0.34) and IL6 (d+=-1.48, 95%CI -2.24to -0.73). Favorable
results were also observed for cellular adhesion molecules, ICAM (d+=-4.32 95%CI -8.37
to -0.26;) and VCAM (d+=-1.61, 95%CI -2.61 to -0.60). Results for lipid disruption indicate
beneficial effect on serum lipid markers TG and LDL (d+=-0.63, 95%CI -0.95 to -0.31; d+=1.15, 95%CI – 1.70 to -0.60, respectively). Finally, results for HDL cholesterol (d+=0.15,
95%CI -0.02 to 0.33) indicate an insignificant effect on this particular serum lipid biomarker.
The ratio of the between-studies variability out of the total variability, I2, was noted to range
from 91.21% to 99.97%, indicating that significant variability is present within the models.
Please refer to Figures 2-11 to view forest plots for desired outcomes of interest pertaining
to CVD related events, inflammation, and dyslipidemia. Significant heterogeneity or
variability was found within the study population.
Mixed-effect Meta-regressions. Meta-regressions using the moderator variable
number of weeks or intervention length were conducted for each of the 7 outcomes of
interest. A significant moderating effect by the variable weeks or intervention length, was
noted for VCAM (β=-0.0607, 95% CI -0.1082 to -0.0148) The MD had a greater beneficial
effect on serum VCAM levels in longer interventions, In addition, researchers note that the
longer subjects adhered to MD interventions, the greater the improvement in HDL
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(β=0.0061, 95% CI 0.001 to 0.01). Intervention length accounted for 40.36% of
heterogeneity between studies for the variable VCAM. In addition, the number of weeks
explained 22.30% of heterogeneity within the study population in regards to MD on HDL.
The moderator weeks accounted for some heterogeneity within the study population for
both VCAM and HDL.
Multivariate Approach
A multilevel technique was used for analysis of both inflammatory biomarkers (k=89)
and serum lipid measures (k=112). When applicable, four diet types were accounted for
during analysis including a balanced Mediterranean diet (k=73) or BMD, enhanced
Mediterranean Diet with mixed nuts (k=23) or MDN, enhanced Mediterranean diet with
olive oil (k=24) or MDOO, and a control group (k=81). Results for BMD, MDN, and MDOO
only will be discussed in this paper as the specific objectives aim to investigate
Mediterranean diet groups only. The multivariate meta-analytic models were conducted for
each outcome of interest using sub-groups of weighted effect sizes. Please refer to Tables
5 and 6 for a summary of each multilevel model.
C-reactive Protein. The multilevel model for CRP was conducted using 41
comparisons clustered within 17 reports. Overall, the multilevel model revealed that a
balanced Mediterranean diet (BMD) and an olive oil-enhanced Mediterranean diet (MDOO)
exerted beneficial effects on CRP that were statistically different from the MDN group (d+=4.44, 95%CI –6.75 to –2.14; d+=-8.41, 95%CI -13.53 to -3.29 respectively). The mixed nutenhanced Mediterranean diet (MDN) was found to have an non-significant effect when
compared to BMD, and MDOO groups (d+=-0.22, 95%CI –2.2 to 1.76). The multilevel
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model for CRP revealed a test of moderator statistic or QM of 25.123 (p.value=<.0001),
suggesting that the efficacy of dietary interventions differed significantly from one another
with good model fit. Please refer to Table 5 to review the results of this multilevel model in
table format.
Interleukin-6. The model for IL6 was conducted with 24 comparisons which
were clustered within 10 reports. Overall, the multilevel model revealed that the BMD,
MDN, and MDOO exerted beneficial effects that were statistically different from each
dietary comparison according to the respective p.values (d+=-13.72, 95%CI –21.23 to –
6.23; d+=-3.74, 95%CI –6.10 to -1.38; d+=-2.97, 95%CI -4.78 to -1.15, respectively). The
multilevel model for IL6 resulted in a QM value of 23.2952 (p.value=.0001), suggesting that
the dietary interventions in question differed significantly from one another to some degree
with good model fit. Please refer to Table 5 in the appendix to review the results of this
multilevel mode in table format.
Intracellular Adhesion Molecule. The multivariate model for ICAM was conducted
with 13 comparisons clustered within 5 reports. Individual p.values at or above 0.05 confirm
that the dietary comparisons did not differ in effect. Overall, the multilevel model revealed
that BMD, MDN, and MDOO groups had a non-significant effect for ICAM serum levels
under mixed-effect assumptions (d+=-2.86, 95%CI –6.03 to 0.31; d+=-2.05, 95%CI –17.56
to 13.46; d+=-1.93, 95% CI -7.123 to 3.26, respectively). The inferential test for moderators
or QM for this multilevel was 6.9250 (p.value=0.1399) suggesting the fit of this model was
not significant. These values correlate with the results as the effect sizes for each dietary
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intervention did not result in statistically significant Cis with variability. Please refer to Table
5 in the appendix to view the results for this multilevel model in table format.
Vascular Cellular Adhesion Molecule. The multivariate meta-analytic model for
VCAM was conducted with 11 comparisons that were clustered within 4 studies. Overall,
the multilevel model revealed that MDOO was beneficial in regards to VCAM serum levels
(d+=-3.31, 95%CI –6.48 to –0.14). Both BMD and MDN dietary interventions were both
found to have an insignificant effect on VCAM that was not significantly different from the
MDOO group (d+=-0.36, 95%CI –2.57 to 1.84; d+=-4.19, 95%CI –8.63 to 0.24,
respectively). The multilevel model for VCAM resulted in a QM value of 39.8860
(p.value=<.0001) suggesting good model fit and that at least one of the dietary
comparison’s effect differed significantly from the others in question. Please refer to table
5 in the appendix to view results for this multilevel model in table format.
Triglycerides. The multivariate model for TG was conducted with 40 comparisons
that were clustered within 17 reports. Overall, the multilevel model revealed that beneficial
effect on TG by BMD that was significantly different from MDN and MDOO groups (d+=3.0, 95%CI –4.91 to -1.08). The enhanced Mediterranean diets with mixed nuts was found
to be insignificant under mixed-effect assumptions and did not differ significantly from one
another (d+=-0.17, 95%CI –6.76 to 6.42; d+=-2.85, 95%CI –9.20 to 3.50 respectively). The
inferential test QM revealed a value of 27.3081 (p.value=<.0001) suggesting good model
fit as well as varying effect of dietary comparisons in question. Please refer to table 6 in
the appendix to review the corresponding results for the TG model in table format.
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Low Density Lipoprotein. The model for LDL was conducted using a total of 34
comparisons clustered within 14 studies. Overall, the multilevel model revealed that the
BMD was beneficial for LDL levels and was significantly different when compared to MDN
and MDOO groups (d+=-3.46, 95%CI –5.53 to –1.38). Both of the enhanced Mediterranean
diets were found to have insignificant effect on LDL markers (d+=-3.37, 95%CI –7.72 to
0.98; d+=-3.5, 95%CI -8.34 to 1.32, respectively). The inferential test QM resulted in a value
of 12.8939 (p.value=0.0118) suggesting decent model fit as well as a varying effect in
regards to the dietary comparisons in question, specifically the BMD group. Please refer to
table 6 to view the results of this multilevel model in table form.
High Density Lipoprotein. The model for HDL involved 38 comparisons clustered
within 16 reports. Overall, the multilevel model revealed that BMD had a significantly
different beneficial effect for HDL serum levels when compared to MDN and MDOO groups
(d+=3.03, 95%CI 1.38 to 4.67). Both enhanced MD groups, MDN and MDOO, revealed
insignificant results that did not vary from one another (d+=3.11, 95%CI -0.20 to 6.43; d+=1.58, 95%CI -4.73 to 1.57, respectively). The inferential test or QM resulted in a value of
18.8379 (p.value=0.0008) suggesting good model fit as well as a varying effect of the
dietary interventions in question, specifically the BMD group. Please refer to table 6 in the
appendix to view the results for the multilevel HDL model in table format.

Moderator Analysis Using Multivariate Approach
Please refer to Table 7 for complete description of moderator results, including point
estimates, 95% confidence intervals, p.values, and corresponding I2 values for each dietary
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comparison. I2 results ranged from 89.28% to 99.95% within all multilevel models using
moderators. Studies included in this analysis varied in terms of intervention length, mean
age, number of female participants, region of study conduction, funding source, participant
recruitment locations, level of intervention, and methodological quality. Please refer to
Table 9 for a complete list of moderators that produced non-significant results. Refer to
Table 10 for a complete list of moderator variables that were unable to be analyzed due to
lack of reporting. Additional significant trending associations for each moderator of interest
can be observed for all CVD related outcomes. Please refer to Tables 8 through 14 to
review important statistics for observed beneficial associations. The effect of the moderator
is presented as mods and is considered an unstandardized beta (β). This value represents
the quantity of how the effect size behaves, whether it is increasing or decreasing based
on each unit of the moderator variable in question. Individual effect sizes under multivariate
assumptions are listed for each diet with the corresponding confidence intervals
representing the efficacy of the reference dietary intervention when compared to other
dietary comparisons and adjusted for number of weeks. The corresponding p.value
represents the significance in variability between the dietary comparison factors.
In regards to design characteristics, intervention length was found to have an overall
moderating for the VCAM model, β=-0.06 (95% CI -0.09 to -0.03) only. In general, BMD
group had greater beneficial effects on biomarkers CRP, IL6, and TG in longer
interventions when compared to MDN, MDOO, and control groups. Both enhanced
Mediterranean diet groups, MDN and MDOO, had an enhanced significant effect on LDL
when adjusted for intervention length and compared to BMD and control diets. The longer
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the intervention length, the MDN group exerted a greater effect on IL6 in longer
interventions while the MDOO group was beneficial for CRP. In addition to number of
weeks, region of study conduction was tested for its moderating effect. Studies conducted
in Europe measuring LDL had moderating effect β=-2.0057 (95% CI -3.1102 to -0.9013).
Results show that when adjusted for study region, BMD exerted a greater beneficial effect
on CRP and TG that differed significantly from the enhanced Mediterranean diet groups.
The MDN comparison groups had a statistically different effect on CRP and ICAM when
compared to BMD and MDOO groups while MDOO groups were more beneficial for CRP
when controlled for study region. In regards to VCAM (k=11), all studies were conducted
in Europe thus resulting in output error during analysis. Researchers eliminated the piece
of code pertaining to factored moderators in order to obtain observable results. Both BMD
and MDN had beneficial effects on VCAM when adjusted for study region. Studies
recruiting patients from a clinical setting acted as an overall moderating in the IL6 model,

β=-3.68 (95% CI -6.99 to -0.37) only. Effect size of BMD on LDL after adjustment of
recruitment location was more beneficial when compared to enhanced Mediterranean diet
groups. The efficacy of the MDOO groups on LDL and CRP were influenced by subject
recruitment and produced statistically different effects when compared to other
Mediterranean diet groups. In regards to ICAM (k=13) and VCAM (k=11), all subjects were
recruited from a clinical setting resulting in errors in analysis output when using the factored
moderator code. Beneficial effects were observed for BMD groups on VCAM and for MDN
groups on ICAM and VCAM once the factored moderator code was eliminated. Funding
source was also tested as a factored moderator for all inflammatory and lipid markers.
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Sources of funding varied between each included study with a categorical classification of
government source, academic source, private source, or multiple sources. Academic
sources of funding had a modulating effect on VCAM, β=-3.57 (95% CI -4.67 to -0.47) as
well as LDL, β=-2.08 (95% CI -3.87 to -0.30). In addition to academic funding sources, a
modulating effect was also noted for private funding sources for TG, β=-0.61 (95% CI -1.19
to -0.03) and LDL, β=-1.28 (95% CI -2.55 to -0.001). Finally, funding from multiple sources
was found to have a modulating effect on TG, β=-0.87 (95% CI -1.50 to -0.23).
Studies within the included population varied in regards to the level of intervention
or supervision provided for subjects participating in the dietary interventions. Responses
included one on one, small group interventions, supervised sessions, unsupervised
sessions, or incentives. As previously stated in the descriptive results, the majority of
studies conducted dietary interventions with small group processes. Due to the categorical
nature of this variable, factored moderator analysis was conducted using the same syntax
stated above. Under random-effect assumptions, small group intervention level had an
overall moderating effect on the inflammatory biomarker, VCAM (β=-2.56, 95%CI -4.71 to
-0.42). In regards to the most common intervention level used in the interventions included
for VCAM specifically, 82% of dietary interventions were conducted in small groups. The
efficacy of the BMD groups on TG and LDL were influenced by small group intervention
studies following adjustment. A beneficial effect was also noted for MDN groups on LDL.
More intimate group sessions also enhanced the effect of the MDOO interventions on both
CRP and LDL.
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Within the included study population, researchers noted variance between reports
based on randomized control trial methodological quality (MQ). In this meta-analysis,
researchers used two measures of methodological quality or risk of bias, previously
described in the methods section of this paper23,27,28. The total score calculated using the
scale adapted by a third party expert (TBHM) from Miller27 and Jadad28 assessment tools,
was introduced as a predictor or moderator variable for each variable in question.
Methodological quality was found to not have an overall moderating effect on any of the
inflammatory or lipid measures. Overall study MQ was found to have influence on the
MDOO groups’ effect on CRP, IL6, and LDL studies after adjustment and comparison to
other interventions. In addition, the effect of MDN groups of IL6 and LDL were also affected
by overall study MQ after adjustment. The magnitude of effect in regards to the BMD group
on IL6 was also found to be affected by study quality.
In regards to population characteristics, multilevel analysis reports that age did not
have an overall moderating effect for any of the outcomes of interest. The effect of the
balanced Mediterranean diet (BMD) on VCAM was found to have a greater beneficial after
adjustment of subject age when compared to other Mediterranean diet groups. The
beneficial effect of olive oil-enhanced Mediterranean diet (MDOO) groups was also
enhanced by mean age for both CRP and VCAM. The mixed nut-enhanced Mediterranean
diet groups (MDN) had statistically different effect on VCAM in older populations when
compared to BMD and MDOO groups. In regards to number of female participants, BMD
efficacy was significantly different than enhanced groups and influenced by number
females reported in the dietary interventions in five out of seven factors. Serum markers
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for CRP, IL6, VCAM, TG and LDL had significant effect sizes after adjusting for the number
of females. Multilevel analysis reports a greater beneficial effect in female subjects
allocated to MDN groups on the following outcomes IL6, ICAM, VCAM, LDL, and HDL. The
MDOO group was more beneficial in female participants for CRP, VCAM, LDL, and HDL.
Risk of bias was low for random sequence generation, allocation, blinding,
incomplete outcome data, selective reporting, and other potential sources of bias for the
many of studies. Low incidence of high risk of bias of included studies. Please refer to
Figure 14 for a complete Risk of Bias Summary.
Discussion
The results of this high-quality meta analysis begin to shed light on the benefits of
consuming a balanced Mediterranean diet as well as additional dietary enhancement with
increased ratios of olive oil or mixed nuts on cardiovascular disease and associated
markers of disease severity. The significant heterogeneity observed in this work was
partially explained by intervention length, recruitment location, funding source, region of
study conduction, and intervention level. In addition, by accounting for each comparison,
researchers were able to further explore interesting associations between a balanced
Mediterranean diet and two vital components needed to achieve the most balanced form,
olive oil and nuts. To our knowledge, this is the first multilevel meta-analysis examining the
efficiacy of different variations of the Mediterranean diet on CVD, inflammatory biomarkers,
and serum lipid measures.
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Our findings that a balanced Mediterranean diet pattern as well as enhanced MDs
with increased ratio of olive oil and mixed nuts is beneficial in reducing CVD related events
and markers of disease severity compliment if not extend previous research efforts.
Previously published meta-analyses published on the MD and CVD risk factors report
similar beneficial effects on inflammatory biomarkers and serum lipid measures22,73,74In
addition, these studies note similar associations in regards to moderator analysis using
intervention length73,74, region of study conduction73,74, and intervention level25. In general,
individuals adhering to a Mediterranean diet saw greater beneficial effects when studies
were conducted in the Mediterranean basin and with longer duration. In the present metaanalysis, as the majority of studies were conducted in Europe, specifically countries located
in the Mediterranean basin, these findings illuminate the possible predictors of
Mediterranean diet food quality, food culture, and overall access to traditional food
components. Researchers also have considered the baseline health parameters for
individuals in the Mediterranean basin. Further investigation is warranted to explore
specific cultural food practices and their impact on cardiovascular health. In addition,
participants who followed a balanced Mediterranean diet for longer interventions, saw
greater reductions in CRP, IL6, and TG. Longer enhanced MD groups had greater effect
on LDL for both mixed nuts and olive oil. Longer adherence to healthy dietary patterns may
prove to be more beneficial for long term health and maintenance periods. Interestingly,
our findings pertaining to intervention level or delivery of educational sessions to promote
adequate compliance to dietary therapies, further extend the results of a recent metaanalysis developed by our research team25. While the majority of studies were conducted
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using small group proceedings, these findings further extend the existing literature on the
importance of more targeted, personal interventions. Small groups may also bring in an
additional peer support aspect, as study participants in the same group may be able to
provide continued motivation from a more relatable source rather than a principal
investigator.
To our knowledge, there is one meta-analysis specifically focusing on a
Mediterraean diet pattern, endothelial function, and inflammation22. This 2014 metaanalysis by Schwingshackl et al22 included 17 randomized control trials totaling 2300
subjects. Overall, researchers noted a significant decrease in markers of endothelial
dysfunction as well as reductions in specific inflammatory cytokines, CRP and IL6, and
intracellular adhesion molecules. Our current findings compliment Schwingshackl et al22 in
that significant reductions were also noted for CRP, IL6, and VCAM specifically.
One notable difference between Schwingshackl et al22 and this present metaanalysis, is that we considered not only a balanced Mediterranean diet pattern but,
additional MD interventions with increased ratios of olive oil and mixed nuts. One
interesting recurrent theme worth noting throughout our multilevel results was the
effectiveness of the enhanced Mediterranean diet with mixed nuts on interleukin-6 as well
as the enhanced Mediterranean diet with olive oil on C-reactive protein. Perhaps these
results begin to describe some of the targeted benefits observed for this specific dietary
pattern. Thus, the question of interest is if health care professionals could provide a more
targeted dietary therapy for these specific inflammatory biomarkers. This association
reoccurring theme warrants further investigation into specific nutrient profiles and overall
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biochemical composition of these two Mediterranean diet staples. These results may
further suggest an underlying biochemical mechanism and or connection between mixed
nuts and interleukin 6 as well as for olive oil and c-reactive protein. Clinicians may
eventually be able to choose to tailor dietary prescriptions depending on a patient’s specific
clinical presentation.
In summary, our research findings suggest a significant cardio-protective effect
exerted by the Mediterranean diet that extends beyond a more general view of the dietary
pattern. By implementing a multilevel meta-analytic approach, researchers were able to
further explore more targeted strategies related to possible clinical predictors. By
implementing a multilevel model, notable associations were observed that may provide
insight in development of targeted dietary prescriptions for specific inflammatory
biomarkers and serum lipid measures. Early detection of rising cellular adhesion molecules
may provide insight to the beginning stages of the inflammatory response allowing for more
rapid preventative care. In patients with existing complications, targeted dietary therapies
using a greater proportion of olive oil may be suitable for patients with chronic systemic
inflammation while an increased ratio of mixed nuts, may be more suitable for a localized
reaction within the endothelium.
Practical Application. The results of this multilevel meta-analysis contribute to the
expanding wealth of evidence related to the Mediterranean diet and health, particularly
cardiovascular related disease, inflammation, and serum lipid disruption. By attempting
moderator analysis with only few variables with an overall effect, this meta-analysis
demonstrates

the

importance

of

thoroughly

reporting

design

characteristics,
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randomization procedures, dietary intervention guidelines, behavioral interventions used,
and tools used for compliance. Having more detailed information for extraction would
allow for additional moderator analysis with hopes of continued identification of potential
predictors that may influence effect size magnitude. This meta-analysis may be influential
in various health care fields (medical, nutrition, and dietetics) as the level of intervention
had significant influence and associations on many outcomes in question. These findings
suggest that small group interventions may prove to be more beneficial and more
motivating in regards to health behavior changes. Most studies that involved dietary
education, enlisted the help of a Registered Dietitian to carry out dietary comparison
instruction. Dietitians should have a primary role in dietary intervention trials as they are
considered experts in the field of nutrition and dietetics. In addition, RDs are trained in
various counseling techniques and strategies that may be implemented when dietary
adherence is poor. These findings extend recent research results concerning
Mediterranean diet education delivered in small group interventions. Garcia, et al25 notes
in another high quality meta-analysis, that significant beneficial effects were found in
studies that focused on small group education and intervention proceedings.
Study Limitations and Strengths. This meta-analysis has several limitations and
strengths. One limitation would be that the significant heterogeneity between the studies
still remains unexplained after both univariate and multilevel analysis. In addition, multiple
coded variables did not have enough data reported to utilize in moderator testing. Due to
inconsistent reporting, we were unable to control for macronutrient distribution, caloric
content, or physical activity level within the models. There is also the potential for
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ecological fallacy considering we did not have access to raw study data for this analysis.
In that, we should be cautious about translating effect size into individual results. One
final note of caution would be the nature of the data, for ICAM and VCAM specifically.
Clinical measures for these markers had larger ranges of serum levels reported, which
should be considered when interpreting results.
There are multiple strengths for this meta-analysis. In regards to the search
strategy implemented, our research team used a comprehensive literature search within
seven electronic databases. A comprehensive coding form and manual was revised
specifically for this paper and used for data extraction that resulted in 93% agreement
between two independent researchers. Lastly, we performed a meta-analysis at two
levels: univariate and multivariate. To our knowledge, this is the first meta-analysis to
account for dependencies within the dataset to further explore dietary dominance and
significant associations with population characteristics across the current literature on this
topic.
Future Research Directions. To our knowledge, this meta-analysis is the first to
implement a multilevel technique to further investigate dietary dominance within the
included sample. Researchers were able to observe some significant associations in
regards to a balanced Mediterranean diet and enhanced Mediterranean diets with greater
proportions of nuts or olive oil. In this analysis, mean differences are correlated due to the
repeated use of sample information from the control group46. In order to further investigate
dietary dominance, researchers have determined that the next logical step in this ongoing
meta-analytic project would be a network meta-analysis47. Only conducted in few reports
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and criticized for complexity, a network meta-analysis (NMA) allows for synthesis of both
direct and indirect evidence observed within a network of trials with three or more
comparison groups47. A NMA allows researchers to simultaneously compare multiple
treatment groups within a single statistical model47. We feel that a NMA would be a vital
statistical model to include within the developing wealth of research pertaining to the
Mediterranean diet considering many studies are conducted with multiple dietary
interventions. By using a network meta-analytic model, researchers would be able to rank
treatment options from most beneficial to least beneficial thus providing more targeted
results per outcome of interest.
Conclusion
The results of the present meta-analysis suggest that adherence to the overall
Mediterranean diet as well as enhanced MD varieties, can have significant beneficial
effects on cardiovascular disease related events, inflammatory biomarkers, and
dyslipidemia. More high- quality intervention studies are needed to evaluate the
relationship between the traditional MD and the specific roles of olive oil and mixed nut
varieties play within this promising dietary pattern, food culture, and lifestyle. This high
quality meta-analysis on the effect of the TMD and enhanced varieties on CVD related
events, inflammatory biomarkers, and dyslipidemia markers contributes to the expanding
wealth of research in favor of the Mediterranean dietary pattern effects on cardiovascular
disease related outcomes.
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Figure 1. PRISMA Figure Outlining the Process of Study Identification, Screening,
Eligibility, and Inclusion
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Note. N, number of participants; recruit, population recruitment; MHC, mild hypercholesteremia; NR, not reported; MD, Mediterranean
diet; LFD, low fat diet; s.lipids, serum lipids; inflam, inflammation; BP, blood pressure; Ob, obesity; WT, weight; endoD, endothelial
dysfunction; OWT, overweight; PREDIMED, Prevención con Dieta Mediterránea; DM, diabetes mellitus; CVDRF, cardiovascular
disease risk factors; MDN, Mediterranean diet enhanced with mixed nuts; MDOO, Mediterranean diet enhanced with olive oil; WC,
waist circumference; Ngenom, nutrigenomic; MD, medical doctor; CHD, coronary heart disease; events, CVD related events; comm,
community; MetS, metabolic syndrome; vas, vascular; T2DM, type 2 diabetes mellitus; WD, Western Diet; CRF, chronic renal failure;
CAD, coronary artery disease; OA, osteoarthritis; NI; no intervention; MDI, Mediterranean diet intervention; MDHI, Mediterranean diet
high intervention; MDLI, Mediterranean diet low intervention; NMD, non Mediterranean diet; MyP, My Pyramid dietary guidelines for
pregnancy and breastfeeding.
Note on Dietary Assessment column:
● Individual: A dietitian performed a dietary assessment, providing individualized needs for caloric intake and recommendations,
for each participant.
● Group: The study provided general dietary recommendations for the participants, such as a range of servings of certain food
groups, calories based on gender, as opposed to tailoring diets to individual needs based on weight and height.
● Supervised: Participants consumed foods in a supervised setting, where the researchers had control over participant food
choices and quantity of food served.
● Unsupervised: Participants food consumption was unsupervised by researchers, such as eating at home

52

Table 2. Publication Bias
Outcome

Egger's

Begg's

Total CVD Events

p=0.0005

p=0.0031

CRP

p=0.0003

p=0.0031

IL6

p=0.0003

p=0.0031

ICAM

p=0.0004

p=0.0031

VCAM

p=0.0706

p=0.6122

TG

p=0.4278

p=0.0002

LDL

p=0.1410

p=0.0026

HDL

p=0.6078

p=0.0812

Note: CVD, cardiovascular disease; CRP, c-reactive protein; IL6, interleukin-6;
ICAM, intracellular adhesion molecule; VCAM, vascular cellular adhesion
molecule; TG, triglycerides; LDL, low density lipoprotein; HDL, high density
lipoprotein.
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Table 3. Summary of Univariate Results, Overall Effect Sizes, Homogeneity
Outcome

k

d+ (95% CI)

Homogeneity of d’s

Random-Effects

Q

I2

p-value

Total
Events

11

-0.3740
(-0.5726 to -0.1753)*

207.0914

98.63 <0.0001

MI

6

-0.3236
(-0.5681 to -0.0791)*

67.7760

97.26 <0.0001

CVD Death

5

-0.4365
(-0.7838 to -0.0891)*

139.3040

99.04 <0.0001

CRP

26

-1.0174
(-1.6963 to -0.3385)*

478.1697

99.45 <0.0001

IL6

17

-1.4823
(-2.2389 to -0.7256)*

607.8397

99.55 <0.0001

ICAM

10

-4.3157
(-8.3708 to -0.2606)*

1330.1552 99.97 <0.0001

VCAM

9

-1.6076
(-2.6176 to -0.5976)*

321.7464

99.69 <0.0001

TG

24

-0.6306
(-0.9481 to -0.3130)*

513.2172

97.38 <0.0001

LDL

23

-1.1505
(-1.7021 to -0.5990)*

625.2637

99.15 <0.0001

Note: MI, myocardial infarction; CVD, cardiovascular disease; CRP, c-reactive protein;
IL6, interleukin-6; ICAM, intracellular adhesion molecule; VCAM, vascular cellular
adhesion molecule; TG, triglycerides; LDL, low density lipoprotein; HDL, high
density lipoprotein; * indicates significant effect; Q represents Cochran’s Q
indicating significance of heterogeneity; I2 represents the magnitude of
heterogeneity; p-value represents the significance of heterogeneity.
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HDL

24

0.1573
(-0.00168 to 0.3314)

178.1119

91.21 <0.0001

Table 4. Moving The Constant Technique
Outcome

k

Weeks

VCAM

9

12

9

52

23

8

23

104

HDL

d+
R2
(95%CI)
-1.0507
44.32%
(-1.9091, 0.1922)*
-3.5121
(-5.1715, 1.8526)*
-1.2384
0.00%
(-3.3518,
0.8750)
0.8898
(-0.0879,
1.8676)

p-value
<0.0001

<0.0001

Note: VCAM, vascular cellular adhesion molecule; k, number of comparisons included
in analysis; d+, effect size; * represents significant effect; R2 indicates the amount of
heterogeneity accounted for; p.value represents significance.
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Table 5. Summary of Multilevel Results, Overall Effect Sizes, and QM--Inflammation
Biomarker k

BMD

MDN

MDOO

QM

p. value

CRP

41

-4.449
(-6.7468
to 2.1430)*

-0.2196
(-2.2006
to
1.7615)

-8.4106
(13.5294
to 3.2918)*

25.1234

<.0001

IL6

24

-3.7366
(-6.0974
to 1.3758)*

-2.9667
(-4.7842
to 1.1493)*

23.2952

.0001

ICAM

13

13.7177
(21.2286
to6.2067)*
-2.8586
(-6.0310
to
0.3139)

-1.9325
(-7.1266
to
3.2617)

6.9250

0.1399

VCAM

11

-2.0525
(17.5600
to
13.4551)
-4.1933
(-8.6259
to
0.2392)

-3.3115
(-6.4809
to 0.1420)*

39.8868

<.0001

-0.3641
(-2.5684
to
1.8402)

Note: CRP, c-reactive protein; IL6, interleukin-6; ICAM, intracellular adhesion molecule;
VCAM; vascular cellular adhesion molecule; *indicates significant results; QM represents
test of moderators; p.value represents significance.
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Table 6. Summary of Multilevel Results, Overall Effect Sizes, and QM-- Lipids
Serum
Lipid
TG

k

BMD

MDN

MDOO

QM

p.value

40

-2.9992
(-4.9145
to1.0839)*

-0.1682
(-6.7587
to
6.4222)

-2.8504 27.3081
(-9.1992
to
3.4985)

<.0001

LDL

34

-3.4582
(5.5324
to1.3841)*

-3.3664
(-7.7156
to
0.9829)

-3.5086 12.8939
(-8.3435
to
1.3263)

0.0118

HDL

38

3.0282
(1.3819
to
4.6746)*

3.1113
(-0.2079
to
6.4304)

-1.5818 18.8379
(-4.7361
to
1.5724)

0.0008

Note: TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
*indicates significant results; QM represents test of moderators; p.value represents
significance of results.
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Table 7. Significant Moderating Effect Under Mixed-Effect Assumptions
Outcome

Moderator

!

95% CI

IL6

recruitment

-3.6840

VCAM

weeks

-0.0622

VCAM

Intervention lvl

-2.5683

VCAM

fund (aca)

-2.5682

TG

fund (private)

-0.6100

TG

fund (multiple)

-0.8664

LDL

region

-2.0057

LDL

fund (aca)

-2.0848

LDL

fund (private)

-1.2758

(-6.9906
0.3774)*
(-0.0948
0.0297)*
(-4.7138
0.4229)*
(-4.6663
0.4700)*
(-1.1929
0.0290)*
(-1.5043
0.2286)*
(-3.1102
0.9013)*
(-3.8684
0.3011)*
(-2.5503
0.0012)*

P.value
to

- 0.0290

to

- 0.0002

to

- 0.0190

to

- 0.0164

to

- 0.0403

to

- 0.0078

to

- 0.0004

to

- 0.0220

to

- 0.0498

Note: IL6, interleukin-6; VCAM, vascular cellular adhesion molecule; lvl, intervention;
LDL, low-density lipoprotein; fund, funding source; aca, academic; !, unstandardized
beta; *indicates significant results; QM represents test of moderators; p.value represents
significance of results.
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Table 8. Non-Significant Moderators
Non-Significant Moderators
Number and proportion of females
Methodological Quality
Number of interventions
Ethnicity estimation
Proportion of participants with any type of disease
Number of participants with any type of disease
Proportion of Participants taking any type of medication
Number of participants taking any type of medication
Type of medication use
Experimental setting
Length of counseling sessions
Number of counseling sessions
Publication year
Language of publication
Proportion of carbohydrate intake (<50% of ≥50%)
Proportion of saturated fat intake (<10% or ≥10%)
Proportion of total fat intake (<30% or ≥30%)
Proportion of protein intake (<15% or ≥15%)
Mean age of sample
Assessment of dietary compliance
Participation in dietary counseling
Population with cardiovascular disease
Population with Type II Diabetes Mellitus
Population with Metabolic Syndrome
59

Population with overweight/obesity
Table 9. Moderators Unable to be Analyzed due to Lack of Reporting
Moderators Unable to be Analyzed
Proportion of Caucasian, Asian, Hispanic, Caribbean
Oral contraceptive/hormone replacement therapy use
Proportion of smokers
Number of smokers
Supplement use
Alcohol intake
Number of alcoholic drinks per week
Type of alcohol consumption
Amount of exercise per week
Type of exercise
Was dietary adherence monitored
Were medications part of the intervention
Total calories
Dietary sodium intake
Dietary potassium intake
Unsaturated fat intake
Saturated fat intake
Cholesterol intake
Fiber intake
Servings of vegetables recommended
Servings of dairy recommended
Servings of wine recommended
Servings of fish recommended
Servings of olive oil recommended
60

Servings of legumes recommended
Servings of meat recommended
Servings of poultry recommended

Table 10. Significant Associations – Weeks
Outcome

Diet

95% CI

I2

P.value

CRP

BMD

97.58

0.0467

CRP

MDOO

97.58

0.0005

IL6

BMD

99.14

0.0009

IL6

MDN

99.14

0.0389

TG

BMD

92.28

0.0021

LDL

MDN

98.03

0.0308

LDL

MDOO

-0.6514 (-1.2934 to 0.0094)*
-2.1013 (-3.2891 to 0.9135)*
-2.0596 (-3.2698 to 0.8493)*
-1.8007 (-3.5096 to 0.0918)*
-2.9992 (-4.9145 to 1.0839)*
-1.2735 (-2.4291 to 0.1179)*
-1.4883 (-2.6436 to 0.3330)*

98.03

0.0116

Note: CRP, c-reactive protein; IL6, interleukin-6; VCAM, vascular cellular adhesion
molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2
represents the magnitude of heterogeneity; p.value represents significance of difference.
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Table 11. Significant Associations --- Females
Outcome

Diet

95% CI

I2

P.value

CRP

BMD

97.78

0.0018

CRP

MDOO

97.78

0.0004

IL6

BMD

99.04

<.0001

IL6

MDN

99.04

0.0145

ICAM

MDN

99.92

0.0014

VCAM

BMD

98.62

0.0042

VCAM

MDN

98.62

0.0017

VCAM

MDOO

98.62

0.0079

TG

BMD

92.28

<.0001

LDL

BMD

97.56

0.0005

LDL

MDN

97.56

0.0002

LDL

MDOO

97.56

<.0001

HDL

MDN

97.56

0.0014

HDL

MDOO

-0.9557 (-1.5542 to 0.3571)*
-2.4291 (-3.7801 to 1.0782)*
-2.2078 (-3.3139 to 1.1016)*
-2.0668 (-3.7244 to 0.4093)*
-9.9019 (-15.9789 to 3.8248)*
-1.6574 (-2.7934 to 0.5214)*
-3.2953 (-5.3489 to 1.2417)*
-2.7371 (-4.7556 to 0.7186)*
-0.6336 (-0.9348 to 0.3324)*
-1.0553 (-1.6537 to 0.4569)*
-2.5194 (-3.8455 to 1.1932)*
-2.7329 (-4.0630 to 1.4028)*
1.4951 (0.5751 to
2.4151)*
0.9567 (0.0683 to
1.8452)*

97.56

0.0348

Note: CRP, c-reactive protein; IL6, interleukin-6; ICAM, intracellular vascular adhesion
molecule; VCAM, vascular cellular adhesion molecule; TG, triglycerides; LDL, low-density
lipoprotein; *indicates significant results; p.value represents significance of difference.
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Table 12. Significant Associations – Age
Outcome

Diet

95% CI

I2

P.value

CRP

MDOO

97.82

0.0387

VCAM

BMD

99.13

0.0128

VCAM

MDN

99.13

0.0123

VCAM

MDOO

-2.9057
(-5.6602 to 0.1512)*
-91.6845
(-163.8491* to 19.5199)
-91.9121
(-163.8968 to 19.9274)*
-91.3928
(-163.3769 to 19.4086)*

99.13

0.0128

Note: CRP, c-reactive protein; VCAM, vascular cellular adhesion molecule; TG,
triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2 represents the
magnitude of heterogeneity; p.value represents significance of difference.
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Table 13. Significant Associations – Region
Outcome

Diet

95% CI

I2

P.value

CRP

BMD

97.05

0.0003

CRP

MDN

97.05

0.0015

CRP

MDOO

97.05

<.0001

ICAM

MDN

99.93

0.0006

VCAM

MDN

99.27

0.0289

TG

BMD

89.28

0.0002

TG

MDN

89.28

0.0479

TG

MDOO

89.28

0.0367

LDL

BMD

96.88

0.0054

LDL

MDOO

-2.5260 (-3.8809 to 1.1711)*
-2.9090 (-4.7087 to 1.1093)*
-3.9153 (-4.7087 to 1.1093)*
-11.6377 (-18.3046 to 4.9707)*
-2.0563 (-3.9014 to 0.2112)*
-1.2591 (-1.9250 to 0.5931)*
-0.8348 (-1.6619 to 0.0077)*
-0.7134 (-1.3673 to 0.0596)*
-0.7551 (-1.2870 to 0.2232)*
-1.0078 (-1.9416 to 0.0741)*

96.88

0.0344

Note: CRP, c-reactive protein; intracellular vascular adhesion molecule; VCAM, vascular
cellular adhesion molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates
significant results; I2 represents the magnitude of heterogeneity; p.value represents
significance of difference..
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Table 14. Significant Associations – Population Recruitment
Outcome
CRP

Diet
MDOO

ICAM

MDN

VCAM

BMD

VCAM

MDN

LDL

BMD

LDL

MDN

LDL

MDOO

95% CI
-2.3576 (-4.1607 to 0.5546)*
-7.6589 (-13.5122 to 1.8057)*
-1.5763 (-2.8827 to 0.2700)*
-2.0563 (-3.9014 to 0.2112)*
-1.0943 (-2.1792 to 0.0095)*
-1.7842 (-3.3721 to 0.1963)*
-1.9969 (-3.5858 to 0.4080)*

I2
97.86

P.value
0.0104

99.95

0.0103

99.27

0.0186

99.27

0.0289

98.10

0.0480

98.10

0.0276

98.10

0.0138

Note: CRP, c-reactive protein; intracellular vascular adhesion molecule; VCAM, vascular
cellular adhesion molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates
significant results; I2 represents the magnitude of heterogeneity; p.value represents
significance of difference.

65

Table 15. Significant Associations – Intervention Level
Outcome
CRP

Diet
MDOO

VCAM

MDN

TG

BMD

LDL

BMD

LDL

MDN

LDL

MDOO

95% CI
-2.2663 (3.5380 to 0.9946)*
-2.0044 (3.5135 1 to 0.4953)*
-0.6762 (1.1267 to 0.2258)*
-1.4003 (2.4459 to 0.3547)*
-1.7488 (3.1393 to 0.3582)*
-1.9578 (3.3444 to 0.5712)*

I2
97.84

P.value
0.0005

99.08

0.0092

92.14

0.0033

98.09

0.0087

98.09

0.0137

98.09

0.0057

Note: CRP, c-reactive protein; VCAM, vascular cellular adhesion molecule; TG,
triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2 represents the
magnitude of heterogeneity; p.value represents significance of difference.
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Table 15. Significant Associations – MQ
Outcome Diet
CRP

IL6

IL6

IL6

LDL

LDL

95% CI

MDOO -2.7137
(-5.3348
to 0.0926)*
BMD
-7.8048
(13.6727
to 1.9369)*
MDN
-7.7562
(13.9929
to 1.5194)*
MDOO -7.0516
(13.2876
to 0.8156)*
MDN
-2.9113
(-5.6745
to 0.1482)*
MDOO -3.1220
(-5.8825
to 0.3616)*

I2

P.value

97.89 0.0424

99.22 0.0091

99.22 0.0148

99.22 0.0267

98.08 0.0389

98.08 0.0266

Note: CRP, c-reactive protein; IL6, interleukin-6; LDL, low-density lipoprotein; *indicates
significant results; I2 represents the magnitude of heterogeneity; p.value represents
significance.
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Figure 2. Forest Plot for Total CVD Events

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
Figure 3. Forest Plot for Myocardial Infarction
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Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
Figure 4. Forest Plot for CVD related Events

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.

Figure 5. Forest Plot for C-reactive Protein
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Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
Figure 6. Forest Plot for Interleukin 6

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
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Figure 7. Forest Plot for ICAM

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.

Figure 8. Forest Plot for VCAM
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Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.

Figure 9. Forest Plot for TG

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
Figure 10. Forest Plot LDL
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Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.

Figure 11. Forest Plot HDL

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
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Figure 12. Meta-regression Plot for VCAM -- Weeks

B=-0.0615, p.value=0.0098, R2=44.32
Note: Number of weeks is on the x-axis; Outcome of interest is on the Y-axis; B is the
unstandardized beta represented amount of change in outcome per week of intervention;
R2 indicates the percentage of variability for by length.

Figure 13. Meta-regression Plot for HDL--Weeks

B=-0.0615, p.value=0.0098, R2=44.32
Note: Number of weeks is on the x-axis; Outcome of interest is on the Y-axis; B is the
unstandardized beta represented amount of change in outcome per week of intervention;
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R2 indicates the percentage of variability for by length.
Figure 14. Risk of Bias Summary
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Appendix
Appendix 1. Comprehensive Search Strategy Details
PubMed (1940s to present)
Terms were searched in all fields; however, field labels were used to restrict
specific terms/phrases to the Medical Subject Headings [Mesh], publication type
[pt] and journal name [ta] fields.
("Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets" OR "Diet,
Mediterranean"[Mesh]) AND ("cardiovascular disease" OR "Cardiovascular
Diseases"[Mesh] OR "cardiovascular diseases" OR "heart disease" OR "heart diseases"
OR CVD OR CVDs OR "Hypertension"[Mesh] OR hypertension OR hypertensive* OR
"high blood pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial infarction" OR
"myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh] OR stroke OR
"Coronary Artery Disease"[Mesh] OR "coronary artery disease" OR "coronary arterial
disease" OR "coronary heart disease" OR "Cerebrovascular Disorders"[Mesh] OR
"Cerebrovascular Disorders" OR "cerebrovascular disease" OR "cerebrovascular
diseases" OR "Atherosclerosis"[Mesh] OR atherosclerosis OR "Arteriosclerosis"[Mesh]
OR arteriosclerosis OR "Peripheral Vascular Diseases"[Mesh] OR "peripheral vascular
diseases" OR "peripheral vascular disease" OR "peripheral angiopathy" OR "peripheral
angiopathies" OR "Peripheral Arterial Disease"[Mesh] OR "peripheral arterial disease"
OR "peripheral arterial diseases" OR "peripheral artery disease" OR "peripheral artery
diseases" OR "Venous Thrombosis"[Mesh] OR "venous thrombosis" OR "venous
thromboses" OR "deep vein thrombosis" OR "deep vein thromboses" OR "Pulmonary
Embolism"[Mesh] OR "pulmonary embolism" OR "pulmonary embolisms" OR
"Dyslipidemias"[Mesh] OR dyslipidemia OR dyslipidemias OR
"Hypercholesterolemia"[Mesh] OR hypercholesterolemia OR hypercholesterolemias OR
"Aortic Valve Stenosis"[Mesh] OR "Aortic Valve Stenosis" OR "aortic valve stenoses"
OR "aortic stenosis" OR "aortic stenoses" OR "Aneurysm"[Mesh] OR Aneurysm OR
aneurysms OR Aneurism OR regurgitation OR prolapse) AND (("clinical"[tiab] AND
"trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR
"random allocation"[mesh] OR "therapeutic use"[sh]) NOT ("Case Reports"[pt] OR
Comment[pt] OR Editorial[pt] OR Letter[pt] OR "case control"[ti] OR "case report"[ti] OR
"case study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR "cohort
studies" [Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up Studies"[mesh] OR
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"Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up study"[ti] OR
rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti])
Results: 568

EMBASE (via Scopus) (1823 to present)
Limits: Article, review, conference papers, journals
All terms (unless otherwise noted) were searched in "Article Title, Abstract,
Keywords". Because of character restrictions in Scopus, this search was run in
parts and assembled using the "Search history".
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR CVD OR CVDs OR hypertension OR hypertensive* OR "high blood
pressure" OR "myocardial infarction" OR "myocardial infarct" OR MI OR "heart attack"
OR stroke OR "coronary artery disease" OR "coronary arterial disease" OR "coronary
heart disease" OR "Cerebrovascular Disorders" OR "cerebrovascular disease" OR
"cerebrovascular diseases" OR atherosclerosis OR arteriosclerosis OR "peripheral
vascular diseases" OR "peripheral vascular disease" OR "peripheral angiopathy" OR
"peripheral angiopathies" OR "peripheral artery disease" OR "peripheral artery
diseases" OR "peripheral arterial disease" OR "peripheral arterial diseases" OR "venous
thrombosis" OR "venous thromboses" OR "deep vein thrombosis" OR "deep vein
thromboses" OR "pulmonary embolism" OR "pulmonary embolisms" OR dyslipidemia
OR dyslipidemias OR hypercholesterolemia OR hypercholesterolemias OR "Aortic
Valve Stenosis" OR "aortic valve stenoses" OR "aortic stenosis" OR "aortic stenoses"
OR aneurysms OR Aneurism OR regurgitation OR prolapse
AND
Option 1: (clinical AND trial)
OR
Option 2: random* OR "therapeutic use"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results: 149
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CINAHL (1981-present)
All terms were searched in all fields (unless otherwise noted)
Excluded: MEDLINE Records
Limited: academic journals, journal article
Due to database limitations, search was run in parts and assembled using the
search history.
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR
"regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (MH "Clinical Trials+") OR "clinical trial" OR random* OR (MH "Random
Assignment") OR "therapeutic use"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results : 40
PsycINFO (1872 to present)
Limits: academic journals
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Due to database limitations, search was run in parts and assembled using the
search history.
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR
"regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (DE "Clinical Trials") OR "clinical trial" OR random* OR (DE "Random
Sampling") OR "therapeutic use"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results: 14
Academic Search Premier (1980s to present)
Limit: Scholarly (Peer Reviewed) Journals
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR
"regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
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(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results: 208
Agricola (1970-present)
Searched in "All Fields"
Limits: academic journals
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR
"regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results: 40
CAB Direct (1973-present)
Limit to Document Type: Journal article and Evidence based research articles
only
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral
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artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR
"regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report"
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR
"cohort study" OR "retrospective study" OR "non-randomized"
Results: 0 results

Appendix 2. Screening Form
updated: 9/23/15
Study ID:
Coder: __________

Mediterranean Diet CVD Meta-Analysis Selection Criteria
Inclusion Criteria
Trials MUST match all of these criteria:

Pre- AND Post-intervention design
[ ]
Mediterranean diet (as a whole, for
example, not just olive oil) for at least
one of the interventions. Can also be
described as Mediterranean-style diet,
hypocaloric Mediterranean diet, etc.
[ ]
Cardiovascular disease events (ex:
MI, CVD related deaths…etc).
[ ]

Exclusion Criteria
Studies CANNOT include any of the
following:

Animal Models [ ]
Surveys [ ]
Commentary [ ]
Symposium Sessions [ ]
Research Support [ ]
Letters [ ]
Position Paper/Viewpoint [
]
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Inflammatory Biomarkers (CRP, IL6,
ICAM, VCAM)

Review [ ]
Guidelines [ ]

[ ]

Epidemiologic Studies [ ]
Cross-sectional Studies [ ]
Observational Studies [ ]
Olive oil only [ ]
Wine only [ ]
Fish only [ ]
Antioxidants only [ ]

Appendix 3. Comprehensive Coding Form and Coding Manual (updated July 2015)
CODER________

Coder (Julia=1, Marisa=2, Other=3)

Study Information
st
ID _______ Study ID (first 3 letters of 1 author’s last name & unique ID#: Pescatello= PES001), ___________________
(Last name, Yr)
PUB_YR ________ Publication year (consider this missing if unpublished)
DATA
________ Estimated year of data collection (earliest date for data collection or manuscript
submission/publication;
if unpublished and date unknown, use year manuscript was acquired; for dissertation or thesis, use year)
LANG
________ Language of report
_________________________
SOURCE________ Publication Type
unpublished

1=English
1=journal

2=Spanish
2=book

3=Japanese

3=thesis/dissertation

4=Other, specify:
4=conference paper

5=

SCORE ________ Impact Score of the Journal (use ISI Web of Knowledge journal citation reports)
JOURNAL NAME _________________________________________________________________________
PUBMED NAME/ ABBR. _________________________________________________________________
FUNDING SOURCE_______ 1= Gov’nt (i.e., CDC, NIH, etc) 2= Academic/University 3= Private 4= Multiple
For all, specify source/grant:
_____________________________________________________________________________
_____
_____________________________________________________________________________
_________
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NOTE_STUDY________ study notes (make note of multiple arms; ex. MD vs. low fat vs. low carb + MD vs. CONTROL):
_____
_________________________________________________________________________________________________
Sample Characteristics (proportion: 0.0- 1.0) Note: IF ethnicity is reported, ETH_EST will be == 0
ETH

________ Ethnicity reported? 1 = yes; 0 = no
PROP_WH
______ Proportion White; whole #____
PROP_BLK
______ Proportion Black/
whole #____
PROP_ASIAN
______ Proportion Asian/ whole #____
PROP_MIX
______ Proportion Mixed
(other)/ whole #____
PROP_HISP
______ Proportion Latino/Hispanic/ whole #____
PROP_CARIB ______ Proportion Caribbean/ whole #____
ETH_EST ________ Assumed ethnicity (0= n/a, 1= White, 2= Asian, 3= Black, 4= Unreported, 5= Hispanic/Latino)

NUM_FemCON
________ # of Females in Sample; Proportion
(##$%&'$( )*)&' (&%,'$):___________
NUM_FemIN1
________ # of Females in Sample; Proportion
(##$%&'$( )*)&' (&%,'$):___________
NUM_FemIN2
________ # of Females in Sample; Proportion
(##$%&'$( )*)&' (&%,'$):___________
NUM_FemIN3
________ # of Females in Sample; Proportion (##$%&'$( )*)&' (&%,'$):___________
REGION________ Location of sample (if unreported, use location of first author as estimate of study location)
1=American city: __________________
US_ZIP_______
2=other US region (city=
unreported):_____________
3=Canada (city: _______________________)
4=Europe (city:
_______________________)
5=South/Central America, Mexico, Caribbean (city: _______________) 6=Africa (city:
_______________________)
7=Asia (city: Osaka, Japan)
8=Australia (city:
_______________________)
POP

________ Population
0=not reported 1=school/college 2=community (senior center, flyers, etc.)
________________
3= clinical/hospital (e.g., cardiac rehab, outpatient clinic, etc.) _______________________________

NOTE_RECRUIT

Notes on recruitment/ sample location __________________________________________________

Risk Characteristics- report values of baseline data (check methods or descriptive tables) KEEP DATA SEPARATE FOR
GROUPS
TOTAL_POP ________ Reported as total sample? (1=yes, 0=no) *if data is collapsed, not separate for groups, chose YES

Mean age (years)

AGE

IN1 n=____
(total sample),
specify
intervention_____
_
AGE

SD for age (years)

AGE_SD

AGE_SD

Characteristic

CONTROL/
COMPARISON
n=____
(total sample)

IN2 n=____
(total sample),
specify
intervention_______
_
AGE

IN3 n=____
(total sample),
specify
intervention_____
_
AGE

AGE_SD

AGE_SD
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Characteristic
Known disease/ chronic
conditions
0= Healthy
3= CVD(s) (i.e., CAD,
PAD, HF, MI)
4= Stroke
5=
Diabetes
6= MetS
7=
Arthritis
8= Dyslipidemia 9=
Obesity
10= Other,
specify:______________
_
11= Multiple, specify
#s:___________
If disease: report prop. &
number
if “healthy” denote 0=
n/a; if missing=“.”
Medication use (0=no,
1= yes)
If yes, report prop &
number; if no meds,
use 0=NA (if missing
=“.”)
Medication Type (if no
meds= 0)
1= β Blockers
2=
Nitrates
+2
3= Ca Channel
Blockers
4= Angiotension
Converting Enzyme
(ACE) Inhibitors
5= Diuretics
6=
Vasodilators
7= NSAIDs
8=
Aspirin
9= Statins
10=Other,
specify:
11= Multiple, specify:
________
BP Medication use (1=
yes, 0=no)
If unreported == “.”
If yes, report prop. &
number
(if “no”=0, NA; if
missing denote=“.”)

CONTROL/
COMPARISON
n=____
(total sample)

IN1 n=____
(total sample),
specify
intervention_____
_

IN2 n=____
(total sample),
specify
intervention_______
_

IN3 n=____
(total sample),
specify
intervention_____
_

DISEASE

DISEASE

DISEASE

DISEASE

PROP_DISEASE

PROP_DISEASE

PROP_DISEASE

NumberDisease

NumberDisease

NumberDisease

MED

MED

MED

MED

PROP_USE
NumberMED

PROP_USE
NumberMED

PROP_USE
NumberMED

PROP_USE
NumberMED

MED_TYPE

MED_TYPE

MED_TYPE

MED_TYPE

BPMedUse

BPMedUse

BPMedUse

BPMedUse

BPMedProp
BPMedNumber

BPMedProp
BPMedNumber

BPMedProp
BPMedNumber

BPMedProp
BPMedNumber

PROP_DISEAS
E
NumberDisease
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Characteristic
If taking meds, is BP
controlled?
yes= 1, if SBP≤140 OR
DBP≤90; no= 0,
SBP>140 OR DBP>90
(*if no BP use == NA)
LIFESTYLE VARIABLES
Oral Contraceptive
(0=no, 1= yes)
OR Hormone
replacement therapy
Smokers/smokers (≤6
months) (0=no,1=yes;
if missing = “.”)
If yes, report smoker
prop. & number
Nutritional
Supplements
Permitted? (0=no,
1=yes)
If yes, specify type
Consume Alcohol?
(0=no, 1=yes)
If yes, how many
drinks/week?
If yes, what type of
alcohol?
Amount of exercise
per week (in min)
Type of exercise (e.g.,
cardio, strength
training)

CONTROL/
COMPARISON
n=____
(total sample)

IN1 n=____
(total sample),
specify
intervention_____
_

IN2 n=____
(total sample),
specify
intervention_______
_

IN3 n=____
(total sample),
specify
intervention_____
_

BPControl

BPControl

BPControl

BPControl

OC_USE
HRT_USE

OC_USE
HRT_USE

OC_USE
HRT_USE

OC_USE
HRT_USE

SMOKE

SMOKE

SMOKE

SMOKE

PROP_SMOKE
NumberSMOKE

PROP_SMOKE
NumberSMOKE

PROP_SMOKE
NumberSMOKE

PROP_SMOKE
NumberSMOKE

SUPP

SUPP

SUPP

SUPP

TYPE

TYPE

TYPE

TYPE

ALC

ALC

ALC

ALC

AMT

AMT

AMT

AMT

ALCTYPE

ALCTYPE

ALCTYPE

ALCTYPE

EX

EX

EX

EX

NOTE_RISK
Notes on risk characteristics relevant to coding
_____________________________________________
Methods & Design
CON_GRP
________ Type of control group used
1= random assignment of individuals to conditions including a non-diet control group,
specify_________________
2= random assignment of individuals to conditions including non-diet control session
3= random assignment of individuals to non-MD condition/diet
4= random assignment of individuals a non-diet control group
5= other, specify: ______________________________________________________________________
Experiment/ Intervention Conditions
EXPERIMENT________ INTERVENTIONS/EXPERIMENTAL CONDITION(S)
1= non-diet control/comparison + 1 intervention

2= non-diet control/comparison + 2 interventions
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3= non-diet control/comparison + 3 interventions
4= diet control/comparison + 1 intervention

5= diet control/comparison + 2 interventions

6= diet control/comparison + 3 interventions

7= crossover design

EXP_SETTING________ Setting of Intervention(s)
1= hospital
fitness center, gym
5= Other, specify: ___________________________________

2= clinic

3= academic/research lab

4=

6= multiple, specify:__________

DIET_MONITOR________ Was diet adherence monitored? (0= none; 1= yes) If yes, specify:
_______________________________________________________________________________________________
___________
BEHAV_TECH__________Behavioral technique/monitoring system used?(0=none, 1=yes) If yes, specify_______________________________________________________________________________________________
___________
Examples: positive reinforcement/contingency management, exercise & lifestyle information/lectures; PA logs, etc.
INTER_LVL________ Level of intervention or supervision used in the study
1=primarily 1-on-1 2=small group processes (supervisor & group members) 3= supervised session(s)
4= unsupervised session(s) 5=incentive (payment based on sessions attended)
6= multiply, specify #’s:_____________________________
NOTE_EXP & METHODS Notes related to study design & delivery of intervention:
____________________________
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Diet Intervention Characteristics
DIET CHARACTERISTICS
LENGTH___(in weeks)
WTGain/WTLoss___
(1=loss, 2=gain, 3=maintain,
4=unspecified)
PART_LOST # of drop outs

CONTROL/
COMPARISON
LENGTH__

IN1

IN2

IN3

LENGTH__

LENGTH__

LENGTH__

WTGain/WTLoss___

WTGain/WTLoss___

WTGain/WTLoss___

WTGain/WTLoss___

MEDS__

MEDS__

MED__TYPE

MED__TYPE

MED__TYPE

DIET__TYPE

DIET__TYPE

DIET__TYPE

ADHERENCE (report %) If
reported as # of sessions
completed, use==
.*%,'$)$/ ($((0*1(
(
x 100)
)*)&' ($((0*1(

Were medications used as
MEDS__
part of the intervention?
(0=no, 1=yes)
If yes, specify
1= β Blockers
2= Nitrates
+2
3= Ca Channel Blockers
4= Angiotension Converting
Enzyme (ACE) Inhibitors
MED__TYPE
5= Diuretics
6=
Vasodilators
7= NSAIDs
8= Aspirin
9= Statins
10=Other,
specify:
11= Multiple, specify: ________
DIET__TYPE
(1=MedDiet, 2=low-fat, 3=high
DIET__TYPE
protein, 4=low-carb, 5=other,
specify)
Provision of Med Diet Foods? (0=no, 1=yes)

MEDS__

If yes, type and amount___
1=olive oi (amt:____)
2=nuts (amt:___)
3=fruits (amt:___)
4=fish (amt:___)
5=dairy (amt:___)
6=multiple
Diet specification reported as a distribution of macronutrients? (0=no, 1=yes)
If yes, specify
PropCHO___
PropSatFAT___
PropTotFAT___
PropPRO___
KCAL_TOTAL_BASE(kcal/day)
KCAL_TOTAL_END (kcal/day)
KCAL_Rx Prescribed kcals per
day
KCAL_REPORT Reported
kcals per day
Energy restriction (kcal or %)

PropCHO___
PropSatFAT___
PropTotFAT___
PropPRO___

PropCHO___
PropSatFAT___
PropTotFAT___
PropPRO___

PropCHO___
PropSatFAT___
PropTotFAT___
PropPRO___

PropCHO___
PropSatFAT___
PropTotFAT___
PropPRO___

____________
___________
____________
____________

____________
___________
____________
____________

____________
___________
____________
____________

____________
___________
____________
____________

87

DIET CHARACTERISTICS
KCAL_RES (unit= kcal) OR
RES_PERCENT (%)
SOD_INTAKE (mg/day)

CONTROL/
COMPARISON

IN1

IN2

IN3

POT_INTAKE (mg/day)
FAT_INTAKE (g/day)
____________
Unsaturated: FAT_UNSAT
____________
____________
Saturated:
FAT_SAT
Cholesterol: FAT_CHOL
Dietary Fiber Intake (g/day)
FIB_INTAKE
Servings/week: Fruit and/or
Vegetables
VEG_SER
Servings/week: Dairy
DAIRY_SER
Servings/week: Wine
WINE_SER
Servings/week: Whole Grains
GRAIN_SER
Servings/week: Fish
FISH_SER
Servings/week: Olive Oil
OIL_SER
Servings/week: Nuts
NUTS_SER
Servings/week: Legumes
LEG_SER
Servings/week:
Red/processed meat
MEAT_SER
Servings/week: Poultry
POUL_SER
Dietary Compliance & Counseling

____________
____________
____________

____________
____________
____________

____________
____________
____________

DI_COMPLIANCE Was
Dietary compliance assessed?
0= No; 1= Yes)
If yes, specify:
(1=FFQ, 2=Food journal,
3=phone interviewing, 4=24 hr
recall, 5=other,specify___)
Was diet adherence
measured pre, during, or post
intervention? (1=pre, 2=during,
3=post, 4=pre,during, and post,
5=pre and post, 6=not reported)
Is a scale used to measure
adherence? (0=no, 1=yes)
If yes, specify type of scale
used___
DI_COUNSELING
Participation in dietary
counseling? 0= no; 1= yes
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CONTROL/
IN1
IN2
IN3
DIET CHARACTERISTICS
COMPARISON
If Dietary Counseling was
provided, report:
____________
____________
____________
____________
COUNSEL_HR hours per
week
____________
____________
____________
____________
COUNSEL_SESS sessions per
week
DIET_TOPIC If Dietary
Counseling was provided,
briefly state topics covered
QoL Was Quality of Life (QoL)
assessed? 0=no, 1=yes, if yes,
report tool or scale
NOTE_DIET Report here any notes relevant to the dietary intervention, counseling, implementation, etc.

# of follow-ups
Interval of follow-ups
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MEDITERRANEAN DIET:
Meta-Analytic Projects

Standard Operating
Procedures (SOP) Coding
Form Manual
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STUDY ID create unique study ID using the first three letters of 1st author’s last name, and
number to denote if multiple ID exists. For example, author is Pescatello= PES001. The
number 001 denotes that it the first article with that study ID.
PUB_YR: Publication year
DATA: Record the earliest date for data collection, manuscript submission or acceptance for
publication. If there is a date of manuscript submission/ acceptance use the publication date. If it
is unpublished and the date is unknown, denote as “.”
LANG: language of report
SCORE: Use the ISI Web of Knowledge journal citation report for score (access through
www.lib.uconn.edu)
• Go to “research assistance”
• Choose “research databases” – choose database by name & type in “Web of Science”
• Choose “additional resources” and “journal citation report”
• Under “select an option”- choose “search for a specific journal” and submit
• Click on “view list of full journal titles;” copy and paste journal name into search
• Record the number under “Impact Factor”
Note: If the journal is not found on ISI Web of Knowledge, you can check the journal’s home
page. If you can find the impact factor score there-use it. Make sure you note in (V8) where
information was found; if still unable to retrieve score, denote as “.”
JOURNAL NAME: Record the full name of the journal here (i.e., American Journal of Sports
Medicine)
PUBMED NAME: Record the PubMed abbreviated name of the journal here (i.e., Am J Sports
Med)
NOTE_STUDY: Record any relevant notes here about above variables.
SAMPLE CHARACTERISTICS: If the following variables are reported in the manuscript, record
as a proportion; values range from 0.0- 1.0.
ETH: Record the ethnicity/ race of subjects as a proportion. For example: If article reports,
“subjects were all white men” the PROP_WH would be 1.0 and the remaining ethnicity
classifications would be 0.0. However, if 18% is reported for Caucasian (or white) ethnicity, the
proportion would be 0.18. If not explicitly stated, denote as MISSING (“.”)
ETH_EST=Ethnicity estimate: when ethnicity is unreported or missing ethnicity will be
assumed White if study was performed in Europe, Australia, or New Zealand; Asian if
conducted in Asia; and Black if conducted in Africa, Hispanic if conducted in Brazil, Mexico. If
location of study is not reported in methods section, use the location of the first author’s
affiliation (i.e., the university or clinical institution author is a part of). Note: IF ethnicity is
reported (i.e., values were recorded for V9), then ETH_EST will be noted with “0”
indicating it is not applicable.
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NUM_FemCON, NUM_FemIN1 (all the way to NUM_FemIN3): Record the number of females
that were in each of the study groups (i.e., intervention group). If there is only a diet + control
design, leave the other variables blank or cross out. However, if multiple interventions exist (i.e.,
control + >1 diet groups), include # of females for each of the specific intervention and use
all the way to NUM_FemIN3 if needed.
REGION: Record the region of where the sample came from with one of the 8 codes. If the
region is not included in the methods, use the location of the first author’s affiliation (i.e., the
university or clinical institution author is a part of).
US_ZIP: If the location is not provided in the article, use the zip code of first author’s affiliation
(i.e., the university or clinical institution author is a part of).
POP: If available, report population; 1=school or college OR 2= community. If patients were
specifically recruited from a clinical setting or community (i.e., cardiac rehabilitation program,
outpatient clinic, senior citizen center, local community center, etc.), make sure to specify.
If population is not described, denote missing with “0.” For example, if authors report “15
healthy men and women were recruited for the study,” this would not be describing the
population and would be coded as 0.
NOTE_RECRUIT: make any notes on recruitment
RISK CHARACTERISTICS -report values provided for baseline sample data. This
information is commonly reported in either 1) the methods section (written in text) OR 2) in a
baseline/ descriptive table. Be careful to note if the data is reported with SD or SEM. Record
data in the way it is presented (mean±SD or mean±SEM) but change on sheet if SEM (just
scratch SD and put SEM). If SEM is used, make sure this is very clear!
TOTAL_POP: If information is provided for each intervention group separately and not in
aggregate form (i.e., mean of total sample), choose “0= no” and use the existing format on
sheet (i.e., enter into separate columns). If reported as total sample (i.e., aggregate form),
choose “1=yes” and only use one column to record data. If article has >2 groups and
reports data for each intervention (i.e. control group, low, moderate, vigorous intensities) use
additional columns in table.
NOTE: For n value, this corresponds to the number in sample you are working with (i.e., either
total sample or for the specific intervention group).
RISK CHARACTERISTIC TABLE: all values should be recorded as metric (i.e., cm, kg).
Any values that are missing, denote with “.”
Use intervention columns to compare multiple groups if there is no true control.
DISEASE: If text describes subjects as “healthy,” “normotensive,” or “normal BP,” choose 0=
subjects were free of disease(s)/ chronic condition(s). If article has clinical population, you may
have more than >1 condition and/ or disease. If all conditions are represented in list, choose
9=multiple and record the specific #s. If there is condition that is not included in the list, choose
8=other and record specifically.
1= Pre-Hypertensive is defined as, SBP 120-139 mmHg Or DBP 80-89 mmHg.
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2= Hypertension Stage 1: SBP 140-159 mmHg Or DBP 90-99 mmHg, Stage 2: SBP ≥160
mmHg Or DBP ≥100 mmHg (ACSM’s Guidelines for Exercise Testing and Prescription, 8th
Edition).
INFLAMMATION: If authors report that inflammation was measured, denote "1" and specify
biomarkers/cytokines. If authors do not report measurement of inflammation, denote "0."
CARDIAC EVENTS MEASURED: If authors report measurement of cardiac events, denote
number corresponding with events. Report prop and or number if reported. Record how it is
measured if it is not in proportion and number of events.
For BP status, only record hypertension or pre-hypertension here IF author has classified
population. DO NOT CLASSIFY BASED ON ORIENTATION BP VALUES. NOTE. If there is no
mention about cardiovascular diseases or chronic conditions and they are not described as
“healthy” denote missing information with “.” DO NOT ASSUME HEALTHY POPULATION.
MED: If authors report that subjects were not taking any medications, choose “0.” If there is no
mention of medication or medication use, code “.” indicating missing information. If article states
medication use, continue to fill in PROP_USE and WholeNumberUse. IF the study reports
medication use but DOES NOT report number of individuals using medication, report missing
with “.” If article states that “medication use and dosage did not change during intervention,”
chose 1=yes for medication use. If article states that medication was discontinued 4 weeks prior
to intervention (i.e., wash out period), choose 0= no for medication use.
MED_TYPE: if there is no medication use, code 0. If article has clinical population, you may
have more than >1 medications. If all medications are represented in list, choose 9=multiple and
record the specific #s. If there are medications used that are not included in the list, choose
8=other and record specifically.
BPMedUse: If MED is “yes,” report if BP medication specifically is taken; if MED was “no” code
as 0.
If MED was a “yes,” BUT article does not include a list of medications used and you cannot
determine if BP agents were included, denote as not reported with “.”
If BPMedUse is “yes,” fill in as much information as possible for BPMedProp, BPMedNumber
and BPControl. If subjects are taking BP Meds their BP should be “controlled,” defined as a
SBP ≤140 mmHg OR DBP ≤90 mmHg—it does not have to be both, just satisfying either the
SBP or DBP cut point.
Oral Contraceptive (OC) or Hormone Replacement Therapy (HRT) use: Report whether
Oral contraceptives, birth control, or HRT were taken by female subjects during the study. If yes
denote “1.” If no denote “0.” If all men subjects, chose=0.
Lifestyle variables (i.e., smoking years, packs/yr; EtOH or alcohol consumption; caffeine
consumption, etc.) are often not reported. Denote missing with “.” and make not of
unreported lifestyle data in V79 NOTE_RISK (can record as “lifestyle variables = missing
data”).
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SMOKING: Report if the study sample included individuals who were currently smoking, or had
a history of smoking. If yes denote “1,” if no denote “0;” if unreported or history of smoking is not
disclosed in either study eligibility criteria (methods) or baseline data table denote missing “.”
NUTRITIONAL SUPPLEMENTS Nutritional supplements allowed during intervention (not as
part of the intervention). If nutritional supplements were allowed during the intervention, indicate
with 1=yes. If nutritional supplements is excluded from the list of “approved” supplements,
indicate with 0=no. If there was no mention of nutritional supplements, denote with “.”.
SUPPLEMENT TYPE 1=Fish oil, 2=Vitamin D, 3=MVI, 4=Calcium, 5=Other, specify:_________
ALCOHOL If participants do not drink alcohol, chose 0=no, if no mention of alcohol in the article
denote with “.”.
DRINKS/WEEK Report number of drinks/week. If participants do not drink alcohol or alcohol
was not mentioned in the article, denote with “.”.
TYPE OF ALCOHOL Indicate which type of alcoholic beverage the participants report to
consume. If more than one type chose “4=multiple” and indicate the number associated with
the consumed beverage. If participants consume another type of alcohol, chose “5=other” and
specify the type of alcohol. If the type of alcohol is not mentioned or participants do not
consume alcohol denote with “.”.
1 = Beer
2 = Wine
3 = Liquor
4 = Multiple, specify which numbers apply: ________
5 = Other, specify: _______
EXERCISE Indicate amount of exercise participants engaged in as min/week. If not reported,
denote with “.”.
EXERCISE TYPE 1=cardio, 2=strength training, 3=stretching/yoga, 4=other, specify_____
NOTE_RISK: Record any additional information about data in table.
Methods & Design
CON_GRP: describes type of control group used in study.
1= non-diet control group (study includes 2 separate groups of people, comprising a diet group
and a control group), specify
2= non-diet control session (study includes same individuals who perform both a diet
intervention and a control session; more common in acute exercise)
3= random assignment of individuals to non-MD condition/diet
4=random assignment of individuals to a non-diet control group
5= other, specify- if there was a non-diet control group (or session) used that involved a
cognitive task, stress management, coping skills, etc. note it here
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EXPERIMENT: describes study design (i.e., parallel or repeated measure or cross-over design).
Independent groups refer to a parallel study design. For example, there are 3 groups: a
control group (non-diet), a Med diet group, and a low-fat diet group. The groups are
independent of one another; they stay in the same group for the entire intervention. Independent
groups are commonly found in training studies (i.e., chronic exercise). Non-independent
groups refer to a repeated measure or cross-over study design. For example, there are 3
conditions: a control session (non-diet), a Med diet group, and a low-fat diet group. Each person
in the intervention will complete each condition serving as their own control. Non-independent
groups are commonly found in acute studies (i.e., a single exercise bout). A crossover design
assigns subjects to each intervention group for a period of time (ex: 4 wks crossover design with
3 dietary conditions: non diet (control), Med Diet, and LF group. each subject will be on each
diet for 4 wks with washout period).
EXP_SETTING Indicate setting. 1= hospital, 2=clinic, 3=academic/research lab, 4=fitness
center/gym, 5=other, specify, 6=multiple, specify.
DIET MONITOR 0=no, 1=yes. Indicate is diet adherence was assessed using food record, food
frequency questionnaire, Med Diet score, etc.
BEHAVIOR 0=no, 1=yes. If yes, specify. (examples: positive reinforcement, contingency
management diet logs, motivational interviewing, cognitive dissonance, health belief model,
etc.) Not food logs. Only if authors specify certain behavior technique.
INTER_LVL: For acute studies specifically, unless author explicitly states exercise occurred in a
group setting/ session- answer 3= supervised. If multiple apply, choose 5= multiple and specify.
For primary one-on-one (=1), choose when study explicitly states individual counselling
sessions or when exercise sessions are conducted with a personal trainer.
NOTES_EXP & METHODS make any notes pertaining to experiment design and or methods.
LENGTH Report length of intervention in weeks.
WTGain/WTLoss Indicate whether the intervention was intended for weight gain, weight loss,
or weight maintenance.
PART_LOST Report the number of participants that dropped out from the study in each group.
Add # of dropouts if various numbers are stated for different parts of the intervention.
ADHERENCE (assessment of study completion): Record exercise adherence (i.e., the
234567879 :7::;3<:
number of sessions completed during intervention) as a percent value, (
) x 100
838=6 :7::;3<:

For control groups, use 100% adherence unless explicitly stated by study that subjects in the
control group were lost during the intervention (i.e., due to sickness, moving, etc).
MED_USE Report whether or not medications were used as part of the intervention.
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YES_MEDS If medications were used as part of the intervention, specify which medication
type(s) was used.
DIET_TYPE Indicate what type of diet the participants in each group followed. If one group
followed a low-carb Mediterranean Diet that would fall in the “5=other” category and specify.
PROVISION OF FOODS Were any specific foods provided to the participants? 0=no, 1=yes.
IF yes, Type and Amount Indicate type and amount of foods provided to participants.
DIET_MACROS Was the diet reported as a distribution of macronutrients? 0=n0, 1=yes.
Specify Macro Distribution
KCAL Please indicate total Kcals consumed, Total Kcals the participants were “prescribed”/told
to consume each day, and total kcals that participants reported that they consumed. If one of
these components is not reported, denote with “.”.
ENERGY RESTRICTION If calories were restricted for any group, report the Kcal restricted
(kcal deficit per day) and/or the percent that energy was restricted. If not reported, denote with
“.”.
SOD_INTAKE Report sodium intake in mg/day.
POT_INTAKE Report potassium intake in mg/day.
FAT_INTAKE Report all fat categories in g/day (from narrative).
FIB_INTAKE Report dietary fiber intake in g/day.
SERVINGS/WEEK For the following sections please report # of servings per week of each food.
If not reported, denote with “.”.
DI_COMPLIANCE Was dietary compliance assessed? 0=no, 1=yes.
SPECIFY COMPLIANCE 0=no, 1=food frequency questionnaire, 2=food journal/diary, 3=phone,
4=24 hr recall, 5=other, specify.
ADHERENCE MEASURED 0=no, 1=pre, 2=during, 3=post, 4=pre, during, and post, 5= pre and
post, 6= not reported.
SCALE USED Examples of a scale to measure adherence would be the Mediterranean Diet
Score.
SPECIFY SCALE Name of scale used.
DI_COUNSELING Participation in dietary counseling? 0=no, 1=yes.
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COUNSEL_HR hours per week
COUNSEL_SESS sessions per week
DIET_TOPIC Topics covered in dietary counseling
QoI Was quality of life assessed? If yes, report tool used to measure.
NOTE_DIET Record any notes pertaining to dietary intervention, counseling.
# FOLLOW UPS Please report the number of follow ups that took place AFTER the intervention
period to monitor maintenance/success of participants.
INTERVAL Please report the interval of follow ups, for example, 3months after intervention
period.

Appendix 4. Single Variant Syntax in R
library ("metafor")
#Pub bias for MD and CVD events
#egger's
regtest(model2,model="lm", data=MedDiet)
#begg's
ranktest(model2, data=MedDiet)
#funnel plot
model2trim=trimfill(model1, data=MedDiet)
funnel(model2trim)
#Pub bias for MD and IL6
#egger's
regtest(model4,model="lm", data=MedDiet)
#begg's
ranktest(model4, data=MedDiet)
#funnel plot
model4trim=trimfill(model4, data=MedDiet)
funnel(model4trim)
#Pub bias for MD and CRP
#egger's
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regtest(model6,model="lm", data=MedDiet)
#begg's
ranktest(model6, data=MedDiet)
#funnel plot
model6trim=trimfill(model6, data=MedDiet)
funnel(model6trim)
#Pub bias for MD and ICAM
#egger's
regtest(model8,model="lm", data=MedDiet)
#begg's
ranktest(model8, data=MedDiet)
#funnel plot
model8trim=trimfill(model8, data=MedDiet)
funnel(model8trim)

#Pub bias for MD and VCAM
#egger's
regtest(model10,model="lm", data=MedDiet)
#begg's
ranktest(model10, data=MedDiet)
#funnel plot
model10trim=trimfill(model10, data=MedDiet)
funnel(model10trim)
#Pub bias for MD and TG
#egger's
regtest(model12,model="lm", data=MedDiet)
#begg's
ranktest(model12, data=MedDiet)
#funnel plot
model10trim=trimfill(model12, data=MedDiet)
funnel(model12trim)
#Pub bias for MD and LDL
#egger's
regtest(model14,model="lm", data=MedDiet)
#begg's
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ranktest(model14, data=MedDiet)
#funnel plot
model12trim=trimfill(model14, data=MedDiet)
funnel(model14trim)
#Pub bias for MD and HDL
#egger's
regtest(model16,model="lm", data=MedDiet)
#begg's
ranktest(model16, data=MedDiet)
#funnel plot
model16trim=trimfill(model16, data=MedDiet)
funnel(model16trim)
library ("metafor")
#Run model for MD and CVD events
model1<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8),
data=MedDiet,method="FE")
model1
model2<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model2
#Run model for MD and IL6
model3<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4),
data=MedDiet,method="FE")
model3
model4<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4),
data=MedDiet,method="REML" , slab= paste(Reference, Year, sep=""))
model4
#Run model for MD and CRP
model5<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5),
data=MedDiet,method="FE")
model5
model6<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model6
#Run model for MD and ICAM
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model7<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6),
data=MedDiet,method="FE")
model7
model8<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model8
#Run model for MD and VCAM
model9<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7),
data=MedDiet,method="FE")
model9
model10<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model10
#Run model for MD and TG
model11<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1),
data=MedDiet,method="FE")
model11
model12<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model12
#Run model for MD and LDL
model13<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2),
data=MedDiet,method="FE")
model13
model14<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model14
#Run model for MD and HDL
model15<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3),
data=MedDiet1,method="FE")
model15
model16<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3),
data=MedDiet1,method="REML", slab= paste(Reference, Year, sep=""))
model16
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table(MedDiet$Diet)
mean(MedDiet$Weeks)
#re run REML models before making forest plots
model2<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model2
model4<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model4
model6<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model6
model8<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model8
model10<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model10
model12<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model12
model14<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model14
model16<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3),
data=MedDiet,method="REML", slab= paste(Reference, Year, sep=""))
model16
#forest plots
#Forest plot MD and CVD events Combined
par("usr")
forest(model2, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.90, font=2, col="black")#to change the size, font, and color of the plot
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op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-0.10,14, "Med Diet and CVD Events") #the first number indicates where the title
starts and the second number how high in the plot
text(c(-4.3,4),13,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us
the position where favors intervention starts and 7 where the position where favors
baseline starts, and they both are at the 22 height in the plot, if you count the number of
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author,
and Favors are in line 22
text(-9.8,13, "Author(s) and Year", pos=4)
text(7.5,13, "d[95%CI]", pos=4)
par(op)
#Forest plot MD and IL6
par("usr")
forest(model4, xlim=c(-29,5), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-10,20, "Med Diet and IL6") #the first number indicates where the title starts and
the second number how high in the plot
text(c(-21,0.3),19,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us
the position where favors intervention starts and 7 where the position where favors
baseline starts, and they both are at the 22 height in the plot, if you count the number of
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author,
and Favors are in line 22
text(-28.5,19, "Author(s) and Year", pos=4)
text(2.5,19, "d[95%CI]", pos=4)
par(op)
#Forest plot MD and CRP
par("usr")
forest(model6, xlim=c(-15,8), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-2,29, "Med Diet and CRP") #the first number indicates where the title starts and
the second number how high in the plot
text(c(-7,3),28,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the
position where favors intervention starts and 7 where the position where favors baseline
starts, and they both are at the 22 height in the plot, if you count the number of authors
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are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and
Favors are in line 22
text(-15,28, "Author(s) and Year", pos=4)
text(8,28, "d[95%CI]", pos=4)
par(op)
#forest plot for Med Diet and ICAM
par("usr")
forest(model8, xlim=c(-13,5), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-2.5,13, "Med Diet and ICAM") #the first number indicates where the title starts and
the second number how high in the plot
text(c(-6,1.5),12,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us
the position where favors intervention starts and 7 where the position where favors
baseline starts, and they both are at the 22 height in the plot, if you count the number of
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author,
and Favors are in line 22
text(-12,12, "Author(s) and Year", pos=4)
text(3,12, "d[95%CI]", pos=4)
par(op)
#forest plot Med Diet and VCAM
par("usr")
forest(model10, xlim=c(-10,9), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-0.5,12, "Med Diet and VCAM") #the first number indicates where the title starts
and the second number how high in the plot
text(c(-4,3),11,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the
position where favors intervention starts and 7 where the position where favors baseline
starts, and they both are at the 22 height in the plot, if you count the number of authors
are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and
Favors are in line 22
text(-9.8,11, "Author(s) and Year", pos=4)
text(6,11, "d[95%CI]", pos=4)
par(op)
#forest plot for Med Diet and TG
par("usr")
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forest(model12, xlim=c(-25,10), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-5,27.5, "Med Diet and TG") #the first number indicates where the title starts and
the second number how high in the plot
text(c(-15,3),27,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the
position where favors intervention starts and 7 where the position where favors baseline
starts, and they both are at the 22 height in the plot, if you count the number of authors
are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and
Favors are in line 22
text(-24,27, "Author(s) and Year", pos=4)
text(7.5,27, "d[95%CI]", pos=4)
par(op)
#forest plot for Med Diet and LDL
par("usr")
forest(model14, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-0.5,25.4, "Med Diet and LDL") #the first number indicates where the title starts
and the second number how high in the plot
text(c(-4.2,3),24,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us
the position where favors intervention starts and 7 where the position where favors
baseline starts, and they both are at the 22 height in the plot, if you count the number of
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author,
and Favors are in line 22
text(-9.20,24, "Author(s) and Year", pos=4)
text(7,24, "d[95%CI]", pos=4)
par(op)
#forest plot for Med Diet and HDL
par("usr")
forest(model16, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2,
col="dark blue", border="black")
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color
of the inserted text in the plot
text (-0.5,27, "Med Diet and HDL") #the first number indicates where the title starts and
the second number how high in the plot
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text(c(-4,3.8),26,c("Favors Baseline", "Favors Intervention")) #here the -8 is telling us
the position where favors intervention starts and 7 where the position where favors
baseline starts, and they both are at the 22 height in the plot, if you count the number of
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author,
and Favors are in line 22
text(-9.8,26, "Author(s) and Year", pos=4)
text(7.5,26, "d[95%CI]", pos=4)
par(op)
#Regressions
#Regression MD and TG
model181<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Weeks, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
model181pred <- predict(model181, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min(wi))/(max(wi) - min(wi))
dietout1= subset(MedDiet,Diet==1 & Outcome==1) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "white", cex=wi, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on TG and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.5, 0.5))
lines(seq(0,208,.1), model181pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model181pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model181pred$ci.ub, lty = "dashed", col="dark blue")
summary(model181)

#Regression MD and LDL
model191<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods=Weeks, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
model191pred <- predict(model191, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
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size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==2) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on LDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-2.0, 2.0))
lines(seq(0,208,.1), model191pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model191pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model191pred$ci.ub, lty = "dashed", col="dark blue")
summary(model191)
#Regression MD and HDL
model201<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=Weeks, data=
MedDiet1, method="REML", slab= paste(Author, sep =","))
model201pred <- predict(model201, newmods=cbind(seq(0,208,.1)))
wi = MedDiet1$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0))
lines(seq(0,208,.1), model201pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model201pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model201pred$ci.ub, lty = "dashed", col="dark blue")
summary(model201)
#create new variable
minweeks=8-MedDiet$Weeks
minweeks

#Regression MD and HDL minweeks
model32<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=minweeks,
data= MedDiet1, method="REML", slab= paste(Author, sep =","))
model32pred <- predict(model32, newmods=cbind(seq(0,208,.1)))
wi = MedDiet1$w_d.ex.
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min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0))
lines(seq(0,208,.1), model32pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model32pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model32pred$ci.ub, lty = "dashed", col="dark blue")
summary(model32)
#create new variable
maxweeks=208-MedDiet$Weeks
maxweeks
#Regression MD and HDL max weeks
model33<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=maxweeks,
data= MedDiet, method="REML", slab= paste(Author, sep =","))
model33pred <- predict(model32, newmods=cbind(seq(0,208,.1)))
wi = MedDiet1$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0))
lines(seq(0,208,.1), model33pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model33pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model33pred$ci.ub, lty = "dashed", col="dark blue")
summary(model33)

#Regression MD and IL6
model211<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=Weeks, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
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model211pred <- predict(model211, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==4) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on IL6 and Effect Size(d)",xlim=c(0, 208), ylim=c(-8.0, 0.6))
lines(seq(0,208,.1), model211pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model211pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model211pred$ci.ub, lty = "dashed", col="dark blue")
summary(model211)
#Regression MD and CRP
model221<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==5), mods=region, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
model221pred <- predict(model221, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==5) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$region,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on CRP and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.5, 0.5))
lines(seq(0,208,.1), model221pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model221pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model221pred$ci.ub, lty = "dashed", col="dark blue")
summary(model221)

#Regression MD and ICAM
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model241<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==6), mods=Weeks, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
model241pred <- predict(model241, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==6) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on ICAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1))
lines(seq(0,208,.1), model241pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model241pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model241pred$ci.ub, lty = "dashed", col="dark blue")
summary(model241)
#Regression MD and VCAM
model261<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=Weeks, data=
MedDiet, method="REML", slab= paste(Author, sep =","))
model261pred <- predict(model261, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5))
lines(seq(0,208,.1), model261pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model261pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model261pred$ci.ub, lty = "dashed", col="dark blue")
summary(model261)
#create new variable
maxweeks=52-MedDiet$Weeks
maxweeks
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#Regression MD and VCAM maxweeks
model27<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=maxweeks,
data= MedDiet, method="REML", slab= paste(Author, sep =","))
model27pred <- predict(model27, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5))
lines(seq(0,208,.1), model27pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model27pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model27pred$ci.ub, lty = "dashed", col="dark blue")
summary(model27)
#create new variable
minweeks=12-MedDiet$Weeks
minweeks
#Regression MD and VCAM minweeks
model31<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=minweeks,
data= MedDiet, method="REML", slab= paste(Author, sep =","))
model31pred <- predict(model31, newmods=cbind(seq(0,208,.1)))
wi = MedDiet$w_d.ex.
min= min(wi, na.rm=TRUE)
max= max(wi, na.rm=TRUE)
size= 0.5 + 3.0 * (wi - min)/(max - min)
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the
subsample we are working on to just plot the observed values of that below
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab =
"Number of Weeks", #Plotting here the observed values of the subsample
ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5))
lines(seq(0,208,.1), model31pred$pred, col = "dark blue") #Plotting here the regression
line and confidence interval of the predictive model
lines(seq(0,208,.1), model31pred$ci.lb, lty = "dashed", col="dark blue")
lines(seq(0,208,.1), model31pred$ci.ub, lty = "dashed", col="dark blue")
summary(model31)
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Appendix 5. Multivariate Syntax in R
library(metafor)
#CRP
#Calculate total number of participants (Ni)
creactive$ni <-unlist(lapply(split(creactive,creactive$study),function(x)
rep(sum(x$ni1)+x$ni2[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.creactivev <- function(x) {creactivev<- matrix(1/x$ni2[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(creactivev) <- x$var
creactivev}
creactiveproV <- lapply(split(creactive,creactive$study),calc.creactivev)
creactiveproV <-as.matrix(bdiag(creactiveproV))
creactiveproV
##Calculating the Weighted Mean ES
creactive$diet <-as.factor(creactive$diet)
dcreactive <- rma.mv(d, var, creactiveproV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = creactive,method="ML")
dcreactive
table(creactive$diet)
#moderators
#moderator Weeks
model1<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$weeks, data =
creactive, method="ML")
summary (model1)
#moderator females
model2<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$fem,data =
creactive, method="ML")
summary (model2)
#moderator proportion of females
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model3<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$propfem,data =
creactive, method="ML")
summary (model3)

#moderator region
model4<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 +
factor(creactive$region),data = creactive, method="ML")
summary (model4)
#moderator population recruit
model5<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(pop),data =
creactive, method="ML")
summary (model5)
#moderator age
model6<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$age,data =
creactive, method="ML")
summary (model6)
#moderator interlvl
model7<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(interlvl),data =
creactive, method="ML")
summary (model7)
#moderator mq
model8<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$mq,data =
creactive, method="ML")
summary (model8)
#moderator pub year
model9<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$Year,data =
creactive, method="ML")
summary (model9)
#moderator total n
model10<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$ni,data =
creactive, method="ML")
summary (model10)
#moderator score
model11<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$score,data =
creactive, method="ML")
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summary (model11)
#moderator number of interventions
model12<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(numinterv),data =
creactive, method="ML")
summary (model12)
#moderator funding source
model13<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(fund),data =
creactive, method="ML")
summary (model13)
#moderator ethnicity estimate
model14<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(ethest),data =
creactive, method="ML")
summary (model14)
#moderator proportion disease
model16<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$diseaseprop,
data = creactive, method="ML")
summary (model16)
#moderator number disease
model17<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$diseasenum,
data = creactive, method="ML")
summary (model17)
#moderator proportion meds
model18<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$medsprop,
data = creactive, method="ML")
summary (model18)
#moderator number meds
model19<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$medsnum,
data = creactive, method="ML")
summary (model19)
#moderator med type
model20<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(medtype), data =
creactive, method="ML")
summary (model20)
#moderator experimental setting
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model21<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$experiset, data
= creactive, method="ML")
summary (model21)

#moderator length of counseling
model22<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$counsellength,
data = creactive, method="ML")
summary (model22)
#moderator number of counseling sessions
model23<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$counselnum,
data = creactive, method="ML")
summary (model23)
#moderator language of publication
model24<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$publang, data
= creactive, method="ML")
summary (model24)
#moderator proportion of carb
model25<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$carbprop, data
= creactive, method="ML")
summary (model25)
#moderator proportion of sat fat
model26<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$satfatprop,
data = creactive, method="ML")
summary (model26)
#moderator proportion of total fat
model27<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$totfatprop,
data = creactive, method="ML")
summary (model27)
#moderator proportion of protein
model28<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$protprop, data
= creactive, method="ML")
summary (model28)
#moderator assessment of dietary compliance
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model29<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(dietcompl), data =
creactive, method="ML")
summary (model29)
#moderator participation in dietary counseling
model30<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$dietcoun, data
= creactive, method="ML")
summary (model30)
#moderator proportion of cvd
model31<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$cvd, data =
creactive, method="ML")
summary (model31)
#moderator proportion of DM
model32<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$dm, data =
creactive, method="ML")
summary (model32)
#moderator proportion of MetS
model33<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$mets, data =
creactive, method="ML")
summary (model33)
#moderator proportion of overweight/obesity
model34<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$obes, data =
creactive, method="ML")
summary (model34)
#IL6
#Calculate total number of participants (ni)
interl$ni <-unlist(lapply(split(interl,interl$study), function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.interv <- function(x) {interv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(interv) <- x$var
interv}
interV <- lapply(split(interl,interl$study),calc.interv)
interV <-as.matrix(bdiag(interV))
interV
##Calculating the Weighted Mean ES
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interl$diet <-as.factor(interl$diet)
dinterl <- rma.mv(d, var, interV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = interl,method="ML")
dinterl
table(interl$diet)
#moderators
#moderator Weeks
model35<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$weeks,data = interl,
method="ML")
summary (model35)
#moderator females
model36<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$fem,data = interl,
method="ML")
summary (model36)
#moderator region
model37<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(region),data = interl,
method="ML")
summary (model37)
#moderator population recruit
model38<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(pop),data = interl,
method="ML")
summary (model38)
#moderator age
model39<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$age,data = interl,
method="ML")
summary (model39)
#moderator interlvl
model40<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data = interl,
method="ML")
summary (model40)
#moderator mq
model41<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$mq,data = interl,
method="ML")
summary (model41)
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#moderator pub year
model42<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$Year,data = interl,
method="ML")
summary (model42)
#moderator total n
model43<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$ni,data = interl,
method="ML")
summary (model43)
#moderator score
model44<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$score,data = interl,
method="ML")
summary (model44)
#moderator funding source
model45<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$fund,data = interl,
method="ML")
summary (model45)
#moderator number of interventions
model45<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$numinterv,data = interl,
method="ML")
summary (model45)
#moderator ethnicity estimate
model46<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(ethest),data = interl,
method="ML")
summary (model46)
#moderator proportion disease
model48<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$diseaseprop, data = interl,
method="ML")
summary (model48)
#moderator number disease
model49<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$diseasenum, data = interl,
method="ML")
summary (model49)
#moderator proportion meds
model50<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$medsprop, data = interl,
method="ML")
summary (model50)
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#moderator number meds
model51<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$medsnum, data = interl,
method="ML")
summary (model51)
#moderator med type
model52<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(medtype), data = interl,
method="ML")
summary (model52)
#moderator experimental setting
model53<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$experiset, data = interl,
method="ML")
summary (model53)
#moderator length of counseling
model54<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$counsellength, data =
interl, method="ML")
summary (model54)
#moderator number of counseling sessions
model55<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$counselnum, data = interl,
method="ML")
summary (model55)
#moderator language of publication
model56<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$publang, data = interl,
method="ML")
summary (model56)
#moderator proportion of carb
model57<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$carbprop, data = interl,
method="ML")
summary (model57)
#moderator proportion of sat fat
model58<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$satfatprop, data = interl,
method="ML")
summary (model58)
#moderator proportion of total fat
model59<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$totfatprop, data = interl,
method="ML")
summary (model59)
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#moderator proportion of protein
model60<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$protprop, data = interl,
method="ML")
summary (model60)
#moderator assessment of dietary compliance
model61<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(dietcompl), data =interl,
method="ML")
summary (model61)
#moderator participation in dietary counseling
model62<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$dietcoun, data = interl,
method="ML")
summary (model62)
#moderator proportion of cvd
model63<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$cvd, data = interl,
method="ML")
summary (model63)
#moderator proportion of DM
model64<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$dm, data = interl,
method="ML")
summary (model64)
#moderator proportion of MetS
model65<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$mets, data = interl,
method="ML")
summary (model65)
#moderator proportion of overweight/obesity
model66<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$obes, data = interl,
method="ML")
summary (model66)
#ICAM
#Calculate total number of participants (Ni)
ICAMdata$ni <-unlist(lapply(split(ICAMdata,ICAMdata$study),function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
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calc.icamv <- function(x) {icamv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(icamv) <- x$var
icamv}
icamV <- lapply(split(ICAMdata, ICAMdata$study),calc.icamv)
icamV <-as.matrix(bdiag(icamV))
icamV
##Calculating the Weighted Mean ES
ICAMdata$diet <-as.factor(ICAMdata$diet)
dicam <- rma.mv(d, var, icamV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = ICAMdata,method="ML")
dicam
table(ICAMdata$diet)

#moderators
#moderator Weeks
model67<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$weeks,data =
ICAMdata, method="ML")
summary (model67)
#moderator females
model68<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$fem,data =
ICAMdata, method="ML")
summary (model68)
#moderator region
model69<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ~ factor(ICAMdata$region),data
= ICAMdata, method="ML")
summary (model69)
#moderator population recruit
model70<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$pop,data =
ICAMdata, method="ML")
summary (model70)
#moderator age
model71<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$age,data =
ICAMdata, method="ML")
summary (model71)
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#moderator interlvl
model72<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data =
ICAMdata, method="ML")
summary (model72)
#moderator mq
model73<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$mq,data = ICAMdata,
method="ML")
summary (model73)
#moderator pub year
model74<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$Year,data =
ICAMdata, method="ML")
summary (model74)

#moderator total n
model75<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$ni,data = ICAMdata,
method="ML")
summary (model75)
#moderator score
model76<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$score,data =
ICAMdata, method="ML")
summary (model76)
#moderator funding source
model77<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(fund),data = ICAMdata,
method="ML")
summary (model77)
#moderator number of interventions
model78<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(numinterv),data =
ICAMdata, method="ML")
summary (model78)
#moderator ethnicity estimate
model80<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(ethest),data = ICAMdata,
method="ML")
summary (model80)
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#moderator proportion disease
model81<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$diseaseprop, data =
ICAMdata, method="ML")
summary (model81)
#moderator number disease
model82<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$diseasenum, data =
ICAMdata, method="ML")
summary (model82)
#moderator proportion meds
model83<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdatal$medsprop, data =
ICAMdata, method="ML")
summary (model83)
#moderator number meds
model84<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$medsnum, data =
ICAMdata, method="ML")
summary (model84)
#moderator med type
model85<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(medtype), data =
ICAMdata, method="ML")
summary (model85)
#moderator experimental setting
model86<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$experiset, data =
ICAMdata, method="ML")
summary (model86)
#moderator length of counseling
model87<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$counsellength, data =
ICAMdata, method="ML")
summary (model87)
#moderator number of counseling sessions
model88<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$counselnum, data =
ICAMdata, method="ML")
summary (model88)
#moderator language of publication
model89<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$publang, data =
ICAMdata, method="ML")
summary (model89)
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#moderator proportion of carb
model90<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$carbprop, data =
ICAMdata, method="ML")
summary (model90)
#moderator proportion of sat fat
model91<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$satfatprop, data =
ICAMdata, method="ML")
summary (model91)
#moderator proportion of total fat
model92<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$totfatprop, data =
ICAMdata, method="ML")
summary (model92)
#moderator proportion of protein
model93<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + i ICAMdata$protprop, data =
ICAMdata, method="ML")
summary (model93)
#moderator assessment of dietary compliance
model94<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(dietcompl), data
=ICAMdata, method="ML")
summary (model94)
#moderator participation in dietary counseling
model95<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$dietcoun, data =
ICAMdata, method="ML")
summary (model95)
#moderator proportion of cvd
model96<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$cvd, data =
ICAMdata, method="ML")
summary (model96)
#moderator proportion of DM
model97<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$dm, data =
ICAMdata, method="ML")
summary (model97)
#moderator proportion of MetS
model98<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$mets, data =
ICAMdata, method="ML")
summary (model98)
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#moderator proportion of overweight/obesity
model99<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$obes, data =
ICAMdata, method="ML")
summary (model99)
#VCAM
#Calculate total number of participants (Ni)
VCAMdata$ni <-unlist(lapply(split(VCAMdata,VCAMdata$study),function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.vcamv <- function(x) {vcamv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(vcamv) <- x$var
vcamv}
vcamV <- lapply(split(VCAMdata,VCAMdata$study),calc.vcamv)
vcamV <-as.matrix(bdiag(vcamV))
vcamV
##Calculating the Weighted Mean ES
VCAMdata$diet <-as.factor(VCAMdata$diet)
dvcam <- rma.mv(d, var, vcamV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = VCAMdata,method="ML")
dvcam
table(VCAMdata$diet)
#moderators
#moderator Weeks
model100<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$weeks,data =
VCAMdata, method="ML")
summary (model100)
#moderator females
model101<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$fem,data =
VCAMdata, method="ML")
summary (model101)
#moderator region
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model102<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$region,data =
VCAMdata, method="ML")
summary (model102)
#moderator population recruit
model103<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$pop,data =
VCAMdata, method="ML")
summary (model103)
#moderator age
model104<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$age,data =
VCAMdata, method="ML")
summary (model104)
#moderator interlvl
model105<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data =
VCAMdata, method="ML")
summary (model105)
#moderator mq
model106<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$mq,data =
VCAMdata, method="ML")
summary (model106)
#moderator pub year
model107<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$Year,data =
VCAMdata, method="ML")
summary (model107)
#moderator total n
model108<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$ni,data =
VCAMdata, method="ML")
summary (model108)
#moderator score
model109<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$score,data =
VCAMdata, method="ML")
summary (model109)
#moderator funding source
model110<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(fund),data = VCAMdata,
method="ML")
summary (model110)
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#moderator number of interventions
model111<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(numinterv),data =
VCAMdata, method="ML")
summary (model111)
#moderator ethnicity estimate
model112<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(ethest),data =
VCAMdata, method="ML")
summary (model112)
#moderator proportion disease
model113<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$diseaseprop, data
= VCAMdata, method="ML")
summary (model113)
#moderator number disease
model114<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$diseasenum, data
= VCAMdata, method="ML")
summary (model114)
#moderator proportion meds
model115<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdatal$medsprop, data =
VCAMdata, method="ML")
summary (model115)
#moderator number meds
model116<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$medsnum, data =
VCAMdata, method="ML")
summary (model116)
#moderator med type
model117<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(medtype), data =
VCAMdata, method="ML")
summary (model117)
#moderator experimental setting
model118<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$experiset, data =
VCAMdata, method="ML")
summary (model118)
#moderator length of counseling
model119<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$counsellength,
data = VCAMdata, method="ML")
summary (model119)
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#moderator number of counseling sessions
model120<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$counselnum, data
= VCAMdata, method="ML")
summary (model120)
#moderator language of publication
model121<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$publang, data =
VCAMdata, method="ML")
summary (model121)
#moderator proportion of carb
model122<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$carbprop, data =
VCAMdata, method="ML")
summary (model122)
#moderator proportion of sat fat
model123<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$satfatprop, data =
VCAMdata, method="ML")
summary (model123)
#moderator proportion of total fat
model124<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$totfatprop, data =
VCAMdata, method="ML")
summary (model124)
#moderator proportion of protein
model125<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$protprop, data =
VCAMdata, method="ML")
summary (model125)
#moderator assessment of dietary compliance
model126<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(dietcompl), data
=VCAMdata, method="ML")
summary (model126)
#moderator participation in dietary counseling
model127<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$dietcoun, data =
VCAMdata, method="ML")
summary (model127)
#moderator proportion of cvd
model128<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$cvd, data =
VCAMdata, method="ML")
summary (model128)
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#moderator proportion of DM
model129<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$dm, data =
VCAMdata, method="ML")
summary (model129)
#moderator proportion of MetS
model130<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$mets, data =
VCAMdata, method="ML")
summary (model130)
#moderator proportion of overweight/obesity
model131<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$obes, data =
VCAMdata, method="ML")
summary (model131)

#TG
#Calculate total number of participants (Ni)
tg$ni <-unlist(lapply(split(tg,tg$study),function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.tgv <- function(x) {tgv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(tgv) <- x$var
tgv}
tgV <- lapply(split(tg,tg$study),calc.tgv)
tgV <-as.matrix(bdiag(tgV))
tgV
##Calculating the Weighted Mean ES
tg$diet <-as.factor(tg$diet)
dtg <- rma.mv(d, var, tgV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = tg,method="ML")
dtg
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table(tg$diet)
#moderators
#moderator Weeks
model132<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$weeks, data = tg,
method="ML")
summary (model132)
#moderator females
model133<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$fem,data = tg, method="ML")
summary (model133)
#moderator region
model134<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(tg$region),data = tg,
method="ML")
summary (model134)
#moderator population recruit
model135<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(pop),data = tg,
method="ML")
summary (model135)
#moderator age
model136<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$age,data = tg, method="ML")
summary (model136)
#moderator interlvl
model137<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(interlvl),data = tg,
method="ML")
summary (model137)
#moderator mq
model138<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$mq,data = tg, method="ML")
summary (model138)
#moderator pub year
model139<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$Year,data = tg, method="ML")
summary (model139)
#moderator total n
model140<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$ni,data = tg, method="ML")
summary (model140)
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#moderator score
model141<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$score,data = tg, method="ML")
summary (model141)
#moderator funding
model142<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(fund),data = tg,
method="ML")
summary (model142)
#moderator number of interventions
model143<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(numinterv),data = tg,
method="ML")
summary (model143)
#moderator ethnicity estimate
model144<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(ethest),data = tg,
method="ML")
summary (model144)
#moderator proportion disease
model145<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$diseaseprop, data = tg,
method="ML")
summary (model145)
#moderator number disease
model146<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$diseasenum, data = tg,
method="ML")
summary (model146)
#moderator proportion meds
model147<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$medsprop, data = tg,
method="ML")
summary (model147)
#moderator number meds
model148<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$medsnum, data = tg,
method="ML")
summary (model148)
#moderator med type
model149<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(medtype), data = tg,
method="ML")
summary (model149)
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#moderator experimental setting
model150<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$experiset, data =tg,
method="ML")
summary (model150)
#moderator length of counseling
model151<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$counsellength, data = tg,
method="ML")
summary (model151)
#moderator number of counseling sessions
model152<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$counselnum, data = tg,
method="ML")
summary (model152)
#moderator language of publication
model153<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$publang, data = tg,
method="ML")
summary (model153)
#moderator proportion of carb
model154<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$carbprop, data = tg,
method="ML")
summary (model154)
#moderator proportion of sat fat
model155<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$satfatprop, data = tg,
method="ML")
summary (model155)
#moderator proportion of total fat
model156<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$totfatprop, data = tg,
method="ML")
summary (model156)

#moderator proportion of protein
model157<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$protprop, data = tg,
method="ML")
summary (model157)
#moderator assessment of dietary compliance
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model158<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(dietcompl), data =tg,
method="ML")
summary (model158)
#moderator participation in dietary counseling
model159<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$dietcoun, data = tg,
method="ML")
summary (model159)
#moderator proportion of cvd
model160<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$cvd, data = tg, method="ML")
summary (model160)
#moderator proportion of DM
model161<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$dm, data = tg, method="ML")
summary (model161)
#moderator proportion of MetS
model162<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$mets, data = tg, method="ML")
summary (model162)
#moderator proportion of overweight/obesity
model163<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$obes, data = tg, method="ML")
summary (model163)
#LDL
#Calculate total number of participants (Ni)
LDLdata$ni <-unlist(lapply(split(LDLdata,LDLdata$study),function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.ldlv <- function(x) {ldlv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(ldlv) <- x$var
ldlv}
ldlV <- lapply(split(LDLdata,LDLdata$study),calc.ldlv)
ldlV <-as.matrix(bdiag(ldlV))
ldlV
##Calculating the Weighted Mean ES
LDLdata$diet <-as.factor(LDLdata$diet)
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dldl <- rma.mv(d, var, ldlV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = LDLdata,method="ML")
dldl
table(LDLdata$diet)
#moderators
#moderator Weeks
model164<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + LDLdata$weeks, data = ldl,
method="ML")
summary (model164)
#moderator females
model165<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + LDLdata$fem,data = ldl,
method="ML")
summary (model165)
#moderator region
model166<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ~ factor(LDLdata$region),data =
ldl, method="ML")
summary (model166)
#moderator population recruit
model167<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ldl$pop),data = ldl,
method="ML")
summary (model167)
#moderator age
model168<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$age,data = ldl, method="ML")
summary (model168)
#moderator interlvl
model169<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ldl$interlvl),data = ldl,
method="ML")
summary (model169)
#moderator mq
model170<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$mq,data = ldl, method="ML")
summary (model170)
#moderator pub year
model171<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$Year,data = ldl, method="ML")
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summary (model171)
#moderator total n
model172<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$ni,data = ldl, method="ML")
summary (model172)
#moderator score
model173<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$score,data = ldl,
method="ML")
summary (model173)
#moderator fund
model174<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(fund),data = ldl,
method="ML")
summary (model174)
#moderator number interventions
model175<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(numinterv),data = ldl,
method="ML")
summary (model175)
#moderator ethnicity estimate
model176<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ethest),data = ldl,
method="ML")
summary (model176)
#moderator proportion disease
model177<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$diseaseprop, data = ldl,
method="ML")
summary (model177)
#moderator number disease
model178<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$diseasenum, data = ldl,
method="ML")
summary (model178)
#moderator proportion meds
model179<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$medsprop, data = ldl,
method="ML")
summary (model179)
#moderator number meds
model180<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$medsnum, data = ldl,
method="ML")
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summary (model180)
#moderator med type
model181<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(medtype), data = ldl,
method="ML")
summary (model181)
#moderator experimental setting
model182<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$experiset, data = ldl,
method="ML")
summary (model182)
#moderator length of counseling
model183<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$counsellength, data = ldl,
method="ML")
summary (model183)
#moderator number of counseling sessions
model184<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$counselnum, data = ldl,
method="ML")
summary (model184)
#moderator language of publication
model185<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$publang, data = ldl,
method="ML")
summary (model185)
#moderator proportion of carb
model186<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$carbprop, data = ldl,
method="ML")
summary (model186)
#moderator proportion of sat fat
model187<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$satfatprop, data = ldl,
method="ML")
summary (model187)
#moderator proportion of total fat
model188<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$totfatprop, data = ldl,
method="ML")
summary (model188)
#moderator proportion of protein
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model189<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$protprop, data = ldl,
method="ML")
summary (model189)
#moderator assessment of dietary compliance
model190<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + factor(dietcompl), data = ldl,
method="ML")
summary (model190)
#moderator participation in dietary counseling
model191<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$dietcoun, data = ldl,
method="ML")
summary (model191)
#moderator proportion of cvd
model192<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$cvd, data = ldl, method="ML")
summary (model192)
#moderator proportion of DM
model193<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$dm, data = ldl, method="ML")
summary (model193)
#moderator proportion of MetS
model194<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$mets, data = ldl,
method="ML")
summary (model194)
#moderator proportion of overweight/obesity
model195<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$obes, data = ldl,
method="ML")
summary (model195)
#HDL
#Calculate total number of participants (Ni)
hdl$ni <-unlist(lapply(split(hdl,hdl$study),function(x)
rep(sum(x$n1i)+x$n2i[1],each=nrow(x))))
#Create Variance-Covariance Matrix for Multiple Comparisons:
calc.hdlv <- function(x) {hdlv<- matrix(1/x$n2i[1] +
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x))
diag(hdlv) <- x$var
hdlv}
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hdlV <- lapply(split(hdl,hdl$study),calc.hdlv)
hdlV <-as.matrix(bdiag(hdlV))
hdlV
##Calculating the Weighted Mean ES
hdl$diet <-as.factor(hdl$diet)
dhdl <- rma.mv(d, var, hdlV, mods = ~ factor(diet) - 1,random = ~
diet|study,struct="UN",data = hdl,method="ML")
dhdl
table(hdl$diet)
#moderators
#moderator Weeks
model196<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$weeks, data = hdl,
method="ML")
summary (model196)
#moderator females
model197<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$fem,data = hdl,
method="ML")
summary (model197)
#moderator region
model198<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(hdl$region),data = hdl,
method="ML")
summary (model198)
#moderator population recruit
model199<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(pop),data = hdl,
method="ML")
summary (model199)
#moderator age
model200<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$age,data = hdl,
method="ML")
summary (model201)
#moderator interlvl
model202<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(interlvl),data = hdl,
method="ML")
summary (model202)
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#moderator mq
model203<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$mq,data = hdl,
method="ML")
summary (model203)
#moderator pub year
model204<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$Year,data = hdl,
method="ML")
summary (model204)
#moderator total population
model205<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$ni,data = hdl, method="ML")
summary (model205)
#moderator score
model206<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$score,data = hdl,
method="ML")
summary (model206)
#moderator funding source
model207<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(fund),data = hdl,
method="ML")
summary (model207)
#moderator number of interventions
model208<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(numinterv),data = hdl,
method="ML")
summary (model208)
#moderator ethnicity estimate
model209<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(ethest),data = hdl,
method="ML")
summary (model209)
#moderator proportion disease
model210<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$diseaseprop, data = hdl,
method="ML")
summary (model210)
#moderator number disease
model211<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$diseasenum, data = hdl,
method="ML")
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summary (model211)
#moderator proportion meds
model212<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$medsprop, data = hdl,
method="ML")
summary (model212)
#moderator number meds
model213<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$medsnum, data = hdl,
method="ML")
summary (model213)
#moderator med type
model214<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(medtype), data = hdl,
method="ML")
summary (model214)
#moderator experimental setting
model215<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$experiset, data = hdl,
method="ML")
summary (model215)
#moderator length of counseling
model216<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$counsellength, data = hdl,
method="ML")
summary (model216)
#moderator number of counseling sessions
model217<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$counselnum, data = hdl,
method="ML")
summary (model217)
#moderator language of publication
model218<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$publang, data = hdl,
method="ML")
summary (model218)
#moderator proportion of carb
model219<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$carbprop, data = hdl,
method="ML")
summary (model219)
#moderator proportion of sat fat
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model220<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$satfatprop, data = hdl,
method="ML")
summary (model220)
#moderator proportion of total fat
model221<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$totfatprop, data = hdl,
method="ML")
summary (model221)
#moderator proportion of protein
model222<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$protprop, data = hdl,
method="ML")
summary (model222)
#moderator assessment of dietary compliance
model223<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + factor(dietcompl), data = hdl,
method="ML")
summary (model223)
#moderator participation in dietary counseling
model224<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$dietcoun, data = hdl,
method="ML")
summary (model224)
#moderator proportion of cvd
model225<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$cvd, data = hdl,
method="ML")
summary (model225)
#moderator proportion of DM
model226<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$dm, data = hdl,
method="ML")
summary (model226)
#moderator proportion of MetS
model227<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$mets, data = hdl,
method="ML")
summary (model227)
#moderator proportion of overweight/obesity
model228<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$obes, data = hdl,
method="ML")
summary (model228)
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